KR101295125B1 - A pharmaceutical with anti-oxidative activity, and a healthful food with the pharmaceutical - Google Patents
A pharmaceutical with anti-oxidative activity, and a healthful food with the pharmaceutical Download PDFInfo
- Publication number
- KR101295125B1 KR101295125B1 KR1020110037075A KR20110037075A KR101295125B1 KR 101295125 B1 KR101295125 B1 KR 101295125B1 KR 1020110037075 A KR1020110037075 A KR 1020110037075A KR 20110037075 A KR20110037075 A KR 20110037075A KR 101295125 B1 KR101295125 B1 KR 101295125B1
- Authority
- KR
- South Korea
- Prior art keywords
- ginseng
- bokbunja
- antioxidant
- schisandra chinensis
- sewage
- Prior art date
Links
- 230000003078 antioxidant effect Effects 0.000 title claims abstract description 65
- 235000013305 food Nutrition 0.000 title claims abstract description 14
- 235000008434 ginseng Nutrition 0.000 claims abstract description 63
- 241000208340 Araliaceae Species 0.000 claims abstract description 58
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 claims abstract description 57
- 235000003140 Panax quinquefolius Nutrition 0.000 claims abstract description 57
- 240000006079 Schisandra chinensis Species 0.000 claims abstract description 49
- 235000008422 Schisandra chinensis Nutrition 0.000 claims abstract description 49
- 239000003963 antioxidant agent Substances 0.000 claims abstract description 46
- 239000000203 mixture Substances 0.000 claims abstract description 40
- 235000011389 fruit/vegetable juice Nutrition 0.000 claims abstract description 26
- 235000012907 honey Nutrition 0.000 claims abstract description 23
- 239000007787 solid Substances 0.000 claims abstract description 16
- YEFOAORQXAOVJQ-RZFZLAGVSA-N schisandrol a Chemical compound C1[C@H](C)[C@@](C)(O)CC2=CC(OC)=C(OC)C(OC)=C2C2=C1C=C(OC)C(OC)=C2OC YEFOAORQXAOVJQ-RZFZLAGVSA-N 0.000 claims abstract description 12
- 235000002789 Panax ginseng Nutrition 0.000 claims abstract description 7
- 240000004371 Panax ginseng Species 0.000 claims abstract description 6
- 241001289529 Fallopia multiflora Species 0.000 claims abstract description 5
- 241000405911 Rehmannia glutinosa Species 0.000 claims abstract description 4
- 239000010865 sewage Substances 0.000 claims description 45
- YEFOAORQXAOVJQ-UHFFFAOYSA-N wuweizischun A Natural products C1C(C)C(C)(O)CC2=CC(OC)=C(OC)C(OC)=C2C2=C1C=C(OC)C(OC)=C2OC YEFOAORQXAOVJQ-UHFFFAOYSA-N 0.000 claims description 20
- 239000000843 powder Substances 0.000 claims description 17
- 235000013376 functional food Nutrition 0.000 claims description 5
- 238000000034 method Methods 0.000 claims description 2
- 235000013373 food additive Nutrition 0.000 claims 1
- 239000002778 food additive Substances 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 abstract description 22
- 241000123889 Rubus chingii Species 0.000 abstract description 3
- 235000006708 antioxidants Nutrition 0.000 description 39
- 239000000523 sample Substances 0.000 description 33
- 238000002474 experimental method Methods 0.000 description 24
- 230000000694 effects Effects 0.000 description 18
- 238000012360 testing method Methods 0.000 description 15
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 14
- 238000002835 absorbance Methods 0.000 description 13
- HHEAADYXPMHMCT-UHFFFAOYSA-N dpph Chemical compound [O-][N+](=O)C1=CC([N+](=O)[O-])=CC([N+]([O-])=O)=C1[N]N(C=1C=CC=CC=1)C1=CC=CC=C1 HHEAADYXPMHMCT-UHFFFAOYSA-N 0.000 description 13
- 239000000284 extract Substances 0.000 description 12
- 238000003860 storage Methods 0.000 description 12
- 210000004369 blood Anatomy 0.000 description 11
- 239000008280 blood Substances 0.000 description 11
- 238000004128 high performance liquid chromatography Methods 0.000 description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 11
- 239000003814 drug Substances 0.000 description 10
- 239000007788 liquid Substances 0.000 description 10
- 238000002360 preparation method Methods 0.000 description 10
- 239000000796 flavoring agent Substances 0.000 description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 8
- 235000019634 flavors Nutrition 0.000 description 8
- 238000002156 mixing Methods 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- ZTOJFFHGPLIVKC-YAFCTCPESA-N (2e)-3-ethyl-2-[(z)-(3-ethyl-6-sulfo-1,3-benzothiazol-2-ylidene)hydrazinylidene]-1,3-benzothiazole-6-sulfonic acid Chemical compound S\1C2=CC(S(O)(=O)=O)=CC=C2N(CC)C/1=N/N=C1/SC2=CC(S(O)(=O)=O)=CC=C2N1CC ZTOJFFHGPLIVKC-YAFCTCPESA-N 0.000 description 7
- 230000002292 Radical scavenging effect Effects 0.000 description 7
- 235000013361 beverage Nutrition 0.000 description 7
- TXEWRVNOAJOINC-UHFFFAOYSA-N ginsenoside Rb2 Natural products CC(=CCCC(OC1OC(COC2OCC(O)C(O)C2O)C(O)C(O)C1O)C3CCC4(C)C3C(O)CC5C6(C)CCC(OC7OC(CO)C(O)C(O)C7OC8OC(CO)C(O)C(O)C8O)C(C)(C)C6CCC45C)C TXEWRVNOAJOINC-UHFFFAOYSA-N 0.000 description 7
- 239000004615 ingredient Substances 0.000 description 7
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 239000009122 Saeng-Ji-Hwang Substances 0.000 description 6
- 201000010099 disease Diseases 0.000 description 6
- 229930182494 ginsenoside Natural products 0.000 description 6
- 239000013641 positive control Substances 0.000 description 6
- 235000019640 taste Nutrition 0.000 description 6
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 5
- 230000032683 aging Effects 0.000 description 5
- 235000009508 confectionery Nutrition 0.000 description 5
- GZYPWOGIYAIIPV-JBDTYSNRSA-N ginsenoside Rb1 Chemical compound C([C@H]1O[C@H]([C@@H]([C@@H](O)[C@@H]1O)O)O[C@@](C)(CCC=C(C)C)[C@@H]1[C@@H]2[C@@]([C@@]3(CC[C@H]4C(C)(C)[C@@H](O[C@H]5[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O5)O[C@H]5[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O5)O)CC[C@]4(C)[C@H]3C[C@H]2O)C)(C)CC1)O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O GZYPWOGIYAIIPV-JBDTYSNRSA-N 0.000 description 5
- YURJSTAIMNSZAE-HHNZYBFYSA-N ginsenoside Rg1 Chemical compound O([C@@](C)(CCC=C(C)C)[C@@H]1[C@@H]2[C@@]([C@@]3(C[C@@H]([C@H]4C(C)(C)[C@@H](O)CC[C@]4(C)[C@H]3C[C@H]2O)O[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)C)(C)CC1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O YURJSTAIMNSZAE-HHNZYBFYSA-N 0.000 description 5
- 229940124595 oriental medicine Drugs 0.000 description 5
- 230000036542 oxidative stress Effects 0.000 description 5
- 239000000546 pharmaceutical excipient Substances 0.000 description 5
- 230000000144 pharmacologic effect Effects 0.000 description 5
- 150000003254 radicals Chemical class 0.000 description 5
- 239000011593 sulfur Substances 0.000 description 5
- 229910052717 sulfur Inorganic materials 0.000 description 5
- UFNDONGOJKNAES-UHFFFAOYSA-N Ginsenoside Rb1 Natural products CC(=CCCC(C)(OC1OC(COC2OC(CO)C(O)C(O)C2O)C(O)C(O)C1O)C3CCC4(C)C3C(O)CC5C6(C)CCC(OC7OC(CO)C(O)C(O)C7OC8OC(CO)C(O)C(O)C8O)C(C)(C)C6CC(O)C45C)C UFNDONGOJKNAES-UHFFFAOYSA-N 0.000 description 4
- 229930006000 Sucrose Natural products 0.000 description 4
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 4
- 150000001720 carbohydrates Chemical class 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- NODILNFGTFIURN-GZPRDHCNSA-N ginsenoside Rb2 Chemical compound C([C@H]1O[C@H]([C@@H]([C@@H](O)[C@@H]1O)O)O[C@@](C)(CCC=C(C)C)[C@@H]1[C@@H]2[C@@]([C@@]3(CC[C@H]4C(C)(C)[C@@H](O[C@H]5[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O5)O[C@H]5[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O5)O)CC[C@]4(C)[C@H]3C[C@H]2O)C)(C)CC1)O[C@@H]1OC[C@H](O)[C@H](O)[C@H]1O NODILNFGTFIURN-GZPRDHCNSA-N 0.000 description 4
- UZIOUZHBUYLDHW-XUBRWZAZSA-N ginsenoside Rf Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@H]2C(C)(C)[C@@H](O)CC[C@]2(C)[C@H]2C[C@@H](O)[C@H]3[C@@]([C@@]2(C1)C)(C)CC[C@@H]3[C@@](C)(O)CCC=C(C)C)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O UZIOUZHBUYLDHW-XUBRWZAZSA-N 0.000 description 4
- 230000036541 health Effects 0.000 description 4
- 241000411851 herbal medicine Species 0.000 description 4
- 210000004185 liver Anatomy 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 238000012545 processing Methods 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 239000005720 sucrose Substances 0.000 description 4
- -1 valeric acid Chemical class 0.000 description 4
- 229930003231 vitamin Natural products 0.000 description 4
- 235000013343 vitamin Nutrition 0.000 description 4
- 239000011782 vitamin Substances 0.000 description 4
- 229940088594 vitamin Drugs 0.000 description 4
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 3
- FBFMBWCLBGQEBU-GYMUUCMZSA-N 20-gluco-ginsenoside-Rf Natural products O([C@](CC/C=C(\C)/C)(C)[C@@H]1[C@H]2[C@H](O)C[C@H]3[C@](C)([C@]2(C)CC1)C[C@H](O[C@@H]1[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)[C@@H](O)[C@H](O)[C@@H](CO)O1)[C@H]1C(C)(C)[C@@H](O)CC[C@]31C)[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 FBFMBWCLBGQEBU-GYMUUCMZSA-N 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- UZIOUZHBUYLDHW-MSJHMJQNSA-N Ginsenoside Rf Natural products O([C@H]1[C@@H](O)[C@H](O)[C@H](CO)O[C@@H]1O[C@@H]1[C@H]2C(C)(C)[C@@H](O)CC[C@]2(C)[C@@H]2[C@](C)([C@@]3(C)[C@H]([C@@H](O)C2)[C@@H]([C@@](O)(CC/C=C(\C)/C)C)CC3)C1)[C@H]1[C@@H](O)[C@@H](O)[C@H](O)[C@H](CO)O1 UZIOUZHBUYLDHW-MSJHMJQNSA-N 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- YURJSTAIMNSZAE-UHFFFAOYSA-N UNPD89172 Natural products C1CC(C2(CC(C3C(C)(C)C(O)CCC3(C)C2CC2O)OC3C(C(O)C(O)C(CO)O3)O)C)(C)C2C1C(C)(CCC=C(C)C)OC1OC(CO)C(O)C(O)C1O YURJSTAIMNSZAE-UHFFFAOYSA-N 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 3
- 235000014633 carbohydrates Nutrition 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 238000012937 correction Methods 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 230000001079 digestive effect Effects 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 230000002255 enzymatic effect Effects 0.000 description 3
- JDCPEKQWFDWQLI-LUQKBWBOSA-N ginsenoside Rc Chemical compound C([C@H]1O[C@H]([C@@H]([C@@H](O)[C@@H]1O)O)O[C@@](C)(CCC=C(C)C)[C@@H]1[C@@H]2[C@@]([C@@]3(CC[C@H]4C(C)(C)[C@@H](O[C@H]5[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O5)O[C@H]5[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O5)O)CC[C@]4(C)[C@H]3C[C@H]2O)C)(C)CC1)O[C@@H]1O[C@@H](CO)[C@H](O)[C@H]1O JDCPEKQWFDWQLI-LUQKBWBOSA-N 0.000 description 3
- PWAOOJDMFUQOKB-WCZZMFLVSA-N ginsenoside Re Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1O[C@H]1[C@H](O[C@@H]2[C@H]3C(C)(C)[C@@H](O)CC[C@]3(C)[C@@H]3[C@@]([C@@]4(CC[C@@H]([C@H]4[C@H](O)C3)[C@](C)(CCC=C(C)C)O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)O)C)(C)C2)O[C@H](CO)[C@@H](O)[C@@H]1O PWAOOJDMFUQOKB-WCZZMFLVSA-N 0.000 description 3
- CBEHEBUBNAGGKC-UHFFFAOYSA-N ginsenoside Rg1 Natural products CC(=CCCC(C)(OC1OC(CO)C(O)C(O)C1O)C2CCC3(C)C2C(O)CC4C5(C)CCC(O)C(C)(C)C5CC(OC6OC(CO)C(O)C(O)C6O)C34C)C CBEHEBUBNAGGKC-UHFFFAOYSA-N 0.000 description 3
- 229960001031 glucose Drugs 0.000 description 3
- 239000008057 potassium phosphate buffer Substances 0.000 description 3
- 235000019614 sour taste Nutrition 0.000 description 3
- 238000001228 spectrum Methods 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- WQZGKKKJIJFFOK-SVZMEOIVSA-N (+)-Galactose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-SVZMEOIVSA-N 0.000 description 2
- CFWRDBDJAOHXSH-SECBINFHSA-N 2-azaniumylethyl [(2r)-2,3-diacetyloxypropyl] phosphate Chemical compound CC(=O)OC[C@@H](OC(C)=O)COP(O)(=O)OCCN CFWRDBDJAOHXSH-SECBINFHSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- 239000004386 Erythritol Substances 0.000 description 2
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 2
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 2
- UIOFUWFRIANQPC-JKIFEVAISA-N Floxacillin Chemical compound N([C@@H]1C(N2[C@H](C(C)(C)S[C@@H]21)C(O)=O)=O)C(=O)C1=C(C)ON=C1C1=C(F)C=CC=C1Cl UIOFUWFRIANQPC-JKIFEVAISA-N 0.000 description 2
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- FLIACVVOZYBSBS-UHFFFAOYSA-N Methyl palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC FLIACVVOZYBSBS-UHFFFAOYSA-N 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- LUSZGTFNYDARNI-UHFFFAOYSA-N Sesamol Natural products OC1=CC=C2OCOC2=C1 LUSZGTFNYDARNI-UHFFFAOYSA-N 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 244000299461 Theobroma cacao Species 0.000 description 2
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 239000003125 aqueous solvent Substances 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 235000010980 cellulose Nutrition 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- CNHRRMQBWQJRPN-UHFFFAOYSA-N chikusetsusaponin LM5 Natural products C1CC(C2(CC(O)C3C(C)(C)C(OC4C(C(O)C(O)C(CO)O4)OC4C(C(O)C(O)C(CO)O4)O)CCC3(C)C2CC2O)C)(C)C2C1C(C)(CCC=C(C)C)OC(C(C(O)C1O)O)OC1COC1OC(CO)C(O)C1O CNHRRMQBWQJRPN-UHFFFAOYSA-N 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 239000000470 constituent Substances 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 235000015872 dietary supplement Nutrition 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 235000011869 dried fruits Nutrition 0.000 description 2
- 235000013399 edible fruits Nutrition 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 2
- 235000019414 erythritol Nutrition 0.000 description 2
- 229940009714 erythritol Drugs 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 235000015203 fruit juice Nutrition 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 229940089161 ginsenoside Drugs 0.000 description 2
- PFSIGTQOILYIIU-UHFFFAOYSA-N ginsenoside Rb3 Natural products CC(=CCCC(C)(O)C1CCC2(C)C3CCC4C(C)(C)C(CCC4(C)C3CC(OC5OC(COC6OCC(O)C(O)C6O)C(O)C(O)C5O)C12C)OC7OC(CO)C(O)C(O)C7OC8OC(CO)C(O)C(O)C8O)C PFSIGTQOILYIIU-UHFFFAOYSA-N 0.000 description 2
- SPFXZQZPHXUJSR-UHFFFAOYSA-N ginsenoside-Rc Natural products CC(=CCCC(C)(OC1OC(CO)C(O)C(O)C1OC2OC(CO)C(O)C2O)C3CCC4(C)C3C(O)CC5C6(C)CCC(OC7OC(CO)C(O)C(O)C7OC8OC(CO)C(O)C(O)C8O)C(C)(C)C6CCC45C)C SPFXZQZPHXUJSR-UHFFFAOYSA-N 0.000 description 2
- ZTQSADJAYQOCDD-UHFFFAOYSA-N ginsenoside-Rd2 Natural products C1CC(C2(CCC3C(C)(C)C(OC4C(C(O)C(O)C(CO)O4)O)CCC3(C)C2CC2O)C)(C)C2C1C(C)(CCC=C(C)C)OC(C(C(O)C1O)O)OC1COC1OCC(O)C(O)C1O ZTQSADJAYQOCDD-UHFFFAOYSA-N 0.000 description 2
- AOGZLQUEBLOQCI-UHFFFAOYSA-N ginsenoside-Re Natural products CC1OC(OCC2OC(OC3CC4(C)C(CC(O)C5C(CCC45C)C(C)(CCC=C(C)C)OC6OC(CO)C(O)C(O)C6O)C7(C)CCC(O)C(C)(C)C37)C(O)C(O)C2O)C(O)C(O)C1O AOGZLQUEBLOQCI-UHFFFAOYSA-N 0.000 description 2
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
- ZWRRJEICIPUPHZ-MYODQAERSA-N gomisin a Chemical compound COC1=C2C=3C(OC)=C(OC)C(OC)=CC=3C[C@](C)(O)[C@@H](C)CC2=CC2=C1OCO2 ZWRRJEICIPUPHZ-MYODQAERSA-N 0.000 description 2
- QBKSWRVVCFFDOT-UHFFFAOYSA-N gossypol Chemical compound CC(C)C1=C(O)C(O)=C(C=O)C2=C(O)C(C=3C(O)=C4C(C=O)=C(O)C(O)=C(C4=CC=3C)C(C)C)=C(C)C=C21 QBKSWRVVCFFDOT-UHFFFAOYSA-N 0.000 description 2
- CATSNJVOTSVZJV-UHFFFAOYSA-N heptan-2-one Chemical compound CCCCCC(C)=O CATSNJVOTSVZJV-UHFFFAOYSA-N 0.000 description 2
- JARKCYVAAOWBJS-UHFFFAOYSA-N hexanal Chemical compound CCCCCC=O JARKCYVAAOWBJS-UHFFFAOYSA-N 0.000 description 2
- 230000003284 homeostatic effect Effects 0.000 description 2
- 238000010832 independent-sample T-test Methods 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 2
- 238000001543 one-way ANOVA Methods 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- HELXLJCILKEWJH-NCGAPWICSA-N rebaudioside A Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HELXLJCILKEWJH-NCGAPWICSA-N 0.000 description 2
- 239000013643 reference control Substances 0.000 description 2
- 239000012088 reference solution Substances 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 230000001953 sensory effect Effects 0.000 description 2
- 235000010356 sorbitol Nutrition 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 229960002920 sorbitol Drugs 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 235000012222 talc Nutrition 0.000 description 2
- 210000002435 tendon Anatomy 0.000 description 2
- NQPDZGIKBAWPEJ-UHFFFAOYSA-N valeric acid Chemical compound CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 description 2
- 150000003722 vitamin derivatives Chemical class 0.000 description 2
- 239000002023 wood Substances 0.000 description 2
- 239000000811 xylitol Substances 0.000 description 2
- 235000010447 xylitol Nutrition 0.000 description 2
- 229960002675 xylitol Drugs 0.000 description 2
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 2
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical class OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 1
- 235000002566 Capsicum Nutrition 0.000 description 1
- 240000004160 Capsicum annuum Species 0.000 description 1
- 235000008534 Capsicum annuum var annuum Nutrition 0.000 description 1
- 235000007862 Capsicum baccatum Nutrition 0.000 description 1
- 102000016938 Catalase Human genes 0.000 description 1
- 108010053835 Catalase Proteins 0.000 description 1
- 235000019750 Crude protein Nutrition 0.000 description 1
- 244000163122 Curcuma domestica Species 0.000 description 1
- 235000003392 Curcuma domestica Nutrition 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- RFSUNEUAIZKAJO-VRPWFDPXSA-N D-Fructose Natural products OC[C@H]1OC(O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-VRPWFDPXSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 206010011878 Deafness Diseases 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
- 239000001512 FEMA 4601 Substances 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 239000004378 Glycyrrhizin Substances 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- 229910002567 K2S2O8 Inorganic materials 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 235000007688 Lycopersicon esculentum Nutrition 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 206010027783 Moaning Diseases 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- IOVCWXUNBOPUCH-UHFFFAOYSA-M Nitrite anion Chemical compound [O-]N=O IOVCWXUNBOPUCH-UHFFFAOYSA-M 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- 229920002230 Pectic acid Polymers 0.000 description 1
- 239000006002 Pepper Substances 0.000 description 1
- 102000003992 Peroxidases Human genes 0.000 description 1
- 235000016761 Piper aduncum Nutrition 0.000 description 1
- 235000017804 Piper guineense Nutrition 0.000 description 1
- 244000203593 Piper nigrum Species 0.000 description 1
- 235000008184 Piper nigrum Nutrition 0.000 description 1
- 241000013557 Plantaginaceae Species 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 241000219050 Polygonaceae Species 0.000 description 1
- 241000205407 Polygonum Species 0.000 description 1
- MUPFEKGTMRGPLJ-RMMQSMQOSA-N Raffinose Natural products O(C[C@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](O[C@@]2(CO)[C@H](O)[C@@H](O)[C@@H](CO)O2)O1)[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 MUPFEKGTMRGPLJ-RMMQSMQOSA-N 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- HELXLJCILKEWJH-SEAGSNCFSA-N Rebaudioside A Natural products O=C(O[C@H]1[C@@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)[C@@]1(C)[C@@H]2[C@](C)([C@H]3[C@@]4(CC(=C)[C@@](O[C@H]5[C@H](O[C@H]6[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O6)[C@@H](O[C@H]6[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O6)[C@H](O)[C@@H](CO)O5)(C4)CC3)CC2)CCC1 HELXLJCILKEWJH-SEAGSNCFSA-N 0.000 description 1
- 235000004789 Rosa xanthina Nutrition 0.000 description 1
- 241000220222 Rosaceae Species 0.000 description 1
- 241000736078 Schisandra sphenanthera Species 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 240000003768 Solanum lycopersicum Species 0.000 description 1
- UQZIYBXSHAGNOE-USOSMYMVSA-N Stachyose Natural products O(C[C@H]1[C@@H](O)[C@H](O)[C@H](O)[C@@H](O[C@@]2(CO)[C@H](O)[C@@H](O)[C@@H](CO)O2)O1)[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@H](CO[C@@H]2[C@@H](O)[C@@H](O)[C@@H](O)[C@H](CO)O2)O1 UQZIYBXSHAGNOE-USOSMYMVSA-N 0.000 description 1
- 244000228451 Stevia rebaudiana Species 0.000 description 1
- OUUQCZGPVNCOIJ-UHFFFAOYSA-M Superoxide Chemical compound [O-][O] OUUQCZGPVNCOIJ-UHFFFAOYSA-M 0.000 description 1
- 235000005764 Theobroma cacao ssp. cacao Nutrition 0.000 description 1
- 235000005767 Theobroma cacao ssp. sphaerocarpum Nutrition 0.000 description 1
- QHOPXUFELLHKAS-UHFFFAOYSA-N Thespesin Natural products CC(C)c1c(O)c(O)c2C(O)Oc3c(c(C)cc1c23)-c1c2OC(O)c3c(O)c(O)c(C(C)C)c(cc1C)c23 QHOPXUFELLHKAS-UHFFFAOYSA-N 0.000 description 1
- 235000021307 Triticum Nutrition 0.000 description 1
- 244000098338 Triticum aestivum Species 0.000 description 1
- MUPFEKGTMRGPLJ-UHFFFAOYSA-N UNPD196149 Natural products OC1C(O)C(CO)OC1(CO)OC1C(O)C(O)C(O)C(COC2C(C(O)C(O)C(CO)O2)O)O1 MUPFEKGTMRGPLJ-UHFFFAOYSA-N 0.000 description 1
- FLUADVWHMHPUCG-OVEXVZGPSA-N Verbascose Natural products O(C[C@H]1[C@H](O)[C@H](O)[C@H](O)[C@@H](OC[C@@H]2[C@H](O)[C@H](O)[C@@H](O)[C@@H](O[C@@]3(CO)[C@H](O)[C@@H](O)[C@@H](CO)O3)O2)O1)[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@H](CO[C@@H]2[C@H](O)[C@@H](O)[C@@H](O)[C@H](CO)O2)O1 FLUADVWHMHPUCG-OVEXVZGPSA-N 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- ZTOJFFHGPLIVKC-CLFAGFIQSA-N abts Chemical compound S/1C2=CC(S(O)(=O)=O)=CC=C2N(CC)C\1=N\N=C1/SC2=CC(S(O)(=O)=O)=CC=C2N1CC ZTOJFFHGPLIVKC-CLFAGFIQSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000001153 anti-wrinkle effect Effects 0.000 description 1
- 239000008047 antioxidant nutrient Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000000513 bioprotective effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000012496 blank sample Substances 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 235000014121 butter Nutrition 0.000 description 1
- 230000000981 bystander Effects 0.000 description 1
- 235000001046 cacaotero Nutrition 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000000378 calcium silicate Substances 0.000 description 1
- 229910052918 calcium silicate Inorganic materials 0.000 description 1
- 235000012241 calcium silicate Nutrition 0.000 description 1
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 1
- 239000012482 calibration solution Substances 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000001728 capsicum frutescens Substances 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 235000014171 carbonated beverage Nutrition 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 235000013351 cheese Nutrition 0.000 description 1
- 235000019219 chocolate Nutrition 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 235000019784 crude fat Nutrition 0.000 description 1
- 235000003373 curcuma longa Nutrition 0.000 description 1
- 229940097362 cyclodextrins Drugs 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- MGJZITXUQXWAKY-UHFFFAOYSA-N diphenyl-(2,4,6-trinitrophenyl)iminoazanium Chemical compound [O-][N+](=O)C1=CC([N+](=O)[O-])=CC([N+]([O-])=O)=C1N=[N+](C=1C=CC=CC=1)C1=CC=CC=C1 MGJZITXUQXWAKY-UHFFFAOYSA-N 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 229920001971 elastomer Polymers 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- HELXLJCILKEWJH-UHFFFAOYSA-N entered according to Sigma 01432 Natural products C1CC2C3(C)CCCC(C)(C(=O)OC4C(C(O)C(O)C(CO)O4)O)C3CCC2(C2)CC(=C)C21OC(C1OC2C(C(O)C(O)C(CO)O2)O)OC(CO)C(O)C1OC1OC(CO)C(O)C(O)C1O HELXLJCILKEWJH-UHFFFAOYSA-N 0.000 description 1
- 239000012259 ether extract Substances 0.000 description 1
- 235000019439 ethyl acetate Nutrition 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 238000001125 extrusion Methods 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 229930002879 flavonoid pigment Natural products 0.000 description 1
- 150000004638 flavonoid pigments Chemical class 0.000 description 1
- 238000007667 floating Methods 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 235000020510 functional beverage Nutrition 0.000 description 1
- DBTMGCOVALSLOR-AXAHEAMVSA-N galactotriose Natural products OC[C@@H]1O[C@@H](O[C@@H]2[C@@H](O)[C@H](CO)O[C@@H](O[C@H]3[C@@H](O)[C@H](O)O[C@@H](CO)[C@@H]3O)[C@@H]2O)[C@H](O)[C@H](O)[C@H]1O DBTMGCOVALSLOR-AXAHEAMVSA-N 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- 235000003969 glutathione Nutrition 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 description 1
- 229960004949 glycyrrhizic acid Drugs 0.000 description 1
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 description 1
- 235000019410 glycyrrhizin Nutrition 0.000 description 1
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 1
- 229930000755 gossypol Natural products 0.000 description 1
- 229950005277 gossypol Drugs 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- LHGVFZTZFXWLCP-UHFFFAOYSA-N guaiacol Chemical class COC1=CC=CC=C1O LHGVFZTZFXWLCP-UHFFFAOYSA-N 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 230000007954 hypoxia Effects 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- VMPHSYLJUKZBJJ-UHFFFAOYSA-N lauric acid triglyceride Natural products CCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCC)COC(=O)CCCCCCCCCCC VMPHSYLJUKZBJJ-UHFFFAOYSA-N 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 230000003859 lipid peroxidation Effects 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 229960003511 macrogol Drugs 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 239000000845 maltitol Substances 0.000 description 1
- 235000010449 maltitol Nutrition 0.000 description 1
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 1
- 229940035436 maltitol Drugs 0.000 description 1
- FZWBNHMXJMCXLU-YRBKNLIBSA-N manninotriose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-YRBKNLIBSA-N 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 229960001855 mannitol Drugs 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- HCZKYJDFEPMADG-TXEJJXNPSA-N masoprocol Chemical compound C([C@H](C)[C@H](C)CC=1C=C(O)C(O)=CC=1)C1=CC=C(O)C(O)=C1 HCZKYJDFEPMADG-TXEJJXNPSA-N 0.000 description 1
- 238000000691 measurement method Methods 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 230000003387 muscular Effects 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- LCLHHZYHLXDRQG-ZNKJPWOQSA-N pectic acid Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)O[C@H](C(O)=O)[C@@H]1OC1[C@H](O)[C@@H](O)[C@@H](OC2[C@@H]([C@@H](O)[C@@H](O)[C@H](O2)C(O)=O)O)[C@@H](C(O)=O)O1 LCLHHZYHLXDRQG-ZNKJPWOQSA-N 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 239000000419 plant extract Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000010318 polygalacturonic acid Substances 0.000 description 1
- 150000008442 polyphenolic compounds Chemical class 0.000 description 1
- 235000013824 polyphenols Nutrition 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- USHAGKDGDHPEEY-UHFFFAOYSA-L potassium persulfate Chemical compound [K+].[K+].[O-]S(=O)(=O)OOS([O-])(=O)=O USHAGKDGDHPEEY-UHFFFAOYSA-L 0.000 description 1
- 235000019394 potassium persulphate Nutrition 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 238000004451 qualitative analysis Methods 0.000 description 1
- MUPFEKGTMRGPLJ-ZQSKZDJDSA-N raffinose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O2)O)O1 MUPFEKGTMRGPLJ-ZQSKZDJDSA-N 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 235000019203 rebaudioside A Nutrition 0.000 description 1
- 239000012925 reference material Substances 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- 230000002000 scavenging effect Effects 0.000 description 1
- ZWRRJEICIPUPHZ-UHFFFAOYSA-N schisandrol B Natural products COC1=C2C=3C(OC)=C(OC)C(OC)=CC=3CC(C)(O)C(C)CC2=CC2=C1OCO2 ZWRRJEICIPUPHZ-UHFFFAOYSA-N 0.000 description 1
- 229930193195 schizandrin Natural products 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 230000009759 skin aging Effects 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- 239000012265 solid product Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- UQZIYBXSHAGNOE-XNSRJBNMSA-N stachyose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO[C@@H]3[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O3)O)O2)O)O1 UQZIYBXSHAGNOE-XNSRJBNMSA-N 0.000 description 1
- 239000012086 standard solution Substances 0.000 description 1
- 229940032147 starch Drugs 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 229960004793 sucrose Drugs 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- 239000002511 suppository base Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 235000013616 tea Nutrition 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 229930003799 tocopherol Natural products 0.000 description 1
- 235000010384 tocopherol Nutrition 0.000 description 1
- 229960001295 tocopherol Drugs 0.000 description 1
- 239000011732 tocopherol Substances 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 235000013976 turmeric Nutrition 0.000 description 1
- 229940005605 valeric acid Drugs 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- FLUADVWHMHPUCG-SWPIJASHSA-N verbascose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO[C@@H]3[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO[C@@H]4[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O4)O)O3)O)O2)O)O1 FLUADVWHMHPUCG-SWPIJASHSA-N 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/20—Natural extracts
- A23V2250/21—Plant extracts
- A23V2250/2124—Ginseng
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Botany (AREA)
- Mycology (AREA)
- Health & Medical Sciences (AREA)
- Nutrition Science (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
본 발명은 오미자(五味子, Schisandra chinensis Baill.), 인삼(人蔘, Panax ginseng C.A. Meyer), 하수오(何首烏, Polygonum multiflorum Thunberg) 및 복분자(覆盆子 Rubus chingii Hu)를 유효성분으로 함유하는 항산화 기능성 조성물에 관한 것이다.
본 발명은 오미자(五味子, Schisandra chinensis Baill.), 인삼(人蔘, Panax ginseng C.A. Meyer), 하수오(何首烏, Polygonum multiflorum Thunberg) 및 복분자(覆盆子 Rubus chingii Hu)를 유효성분로 함유하되, 생지황(生地黃, Rehmannia glutinosa (Gaertner) Liboschitz)) 즙 및 꿀을 추가하여 고제(膏劑)로 제형화된 항산화 기능성 조성물 및 식품에 관한 것이다. The present invention is an antioxidant functional composition containing Schisandra chinensis Baill., Ginseng ( Panax ginseng CA Meyer), Shao (何首烏, Polygonum multiflorum Thunberg) and Bokbunja ( Rubus chingii Hu) as an active ingredient It is about.
The present invention contains Schisandra chinensis Baill. (Omija), Ginseng (人蔘, Panax ginseng CA Meyer), Shou (何首烏, Polygonum multiflorum Thunberg) and Bokbunja (覆盆子Rubus chingii Hu) as an active ingredient,生地黄, Rehmannia glutinosa (Gaertner) Liboschitz)) relates to an antioxidant functional composition and food formulated as a solid by adding juice and honey.
Description
본 발명은 오미자(五味子, Schisandra chinensis Baill.), 인삼(人蔘, Panax ginseng C.A. Meyer), 하수오(何首烏, Polygonum multiflorum Thunberg) 및 복분자(覆盆子 Rubus chingii Hu)를 유효성분으로 함유하는 항산화 기능성 조성물에 관한 것이다.The present invention is an antioxidant functional composition containing Schisandra chinensis Baill., Ginseng ( Panax ginseng CA Meyer), Shao (何首烏, Polygonum multiflorum Thunberg) and Bokbunja ( Rubus chingii Hu) as an active ingredient It is about.
본 발명은 오미자(五味子, Schisandra chinensis Baill.), 인삼(人蔘, Panax ginseng C.A. Meyer), 하수오(何首烏, Polygonum multiflorum Thunberg) 및 복분자(覆盆子 Rubus chingii Hu)를 유효성분로 함유하되, 생지황(生地黃, Rehmannia glutinosa (Gaertner) Liboschitz)) 즙 및 꿀을 추가하여 고제(膏劑)로 제형화된 항산화 기능성 조성물 및 식품에 관한 것이다. The present invention contains Schisandra chinensis Baill. (Omija), Ginseng (人蔘, Panax ginseng CA Meyer), Shou (何首烏, Polygonum multiflorum Thunberg) and Bokbunja (覆盆子Rubus chingii Hu) as an active ingredient,生地黄, Rehmannia glutinosa (Gaertner) Liboschitz)) relates to an antioxidant functional composition and food formulated as a solid by adding juice and honey.
활성산소와 자유 라디칼에 따른 산화적 스트레스는 지질, 단백질, DNA, 효소 등의 변성 및 파괴를 유발하고 이로 인해 노화 및 각종 질병이 발생된다는 것이 알려져 왔다.Oxidative stress due to free radicals and free radicals has been known to cause denaturation and destruction of lipids, proteins, DNA, enzymes and the like, thereby causing aging and various diseases.
즉 산화적 스트레스를 견딜 수 있는 항산화 물질의 생체방어력에 이상이 생기거나 과도한 활성산소 및 자유 라디칼에 노출될 경우, 균형이 깨어져서 기질, 단백질, DNA 등이 비가역적으로 파괴되고, 그 결과 노화 및 암, 복합성 동맥경화, 관절염 및 파킨슨병 등과 같은 각종 질병이 유발되게 된다.In other words, if the bioprotective ability of antioxidants that can withstand oxidative stress or exposure to excessive free radicals and free radicals, the balance is broken and irreversible destruction of the substrate, protein, DNA, etc. As a result, aging and cancer Various diseases such as complex arteriosclerosis, arthritis and Parkinson's disease are caused.
여기에서, 항산화 물질로 작용되는 것은 효소계와 비효소계로 나눌 수 있는데, 슈퍼옥사이드디스퓨타제(SOD), 카탈라아제(catalase), 퍼옥시다아제 (peroxidase) 등의 항산화 효소와 비타민 C, E, 글루타치온(glutathione) 등의 비효소계 물질이 그것이다.
Here, the action of antioxidants can be divided into enzymatic and non-enzymatic systems, including antioxidant enzymes such as superoxide disputase (SOD), catalase, and peroxidase, and vitamin C, E, and glutathione. Non-enzymatic substances such as).
한편 산화적 스트레스에 기인한 질병을 예방하고 개선하기 위해서, 항산화제를 개발하거나, 또는 항산화 효소의 발현을 유도하거나 비효소계 항산화 물질을 함유하는 약학제제 및 기능성 식품을 개발하는 방향 등의 연구가 진행되어 왔다.
Meanwhile, in order to prevent and improve diseases caused by oxidative stress, researches on developing antioxidants, inducing the expression of antioxidant enzymes, or developing pharmaceuticals and functional foods containing non-enzymatic antioxidants are in progress. Has been.
지금까지 개발된 합성 항산화제로는 BHA(butylated hydroxyl anisole), BHT(butylated hydroxyl toluene) 및 NDGA(nordihydro-guaiaretic acid) 등이 있고, 천연 항산화제는 토코페롤(tocopherol), 고시폴(gossypol), 세사몰(sesamol), 레시틴(lecitthin), 세파린(cephalin), 고추의 에테르 추출성분, 소맥배아, 대두, 후추, 토마토에서 얻은 추출물들, 주로 플로보노이드계 색소들의 추출액 등이 있다.
Synthetic antioxidants developed so far include butylated hydroxyl anisole (BHA), butylated hydroxyl toluene (BHT) and nordihydro-guaiaretic acid (NDGA), and natural antioxidants are tocopherol, gossypol and sesamol. (sesamol), lecithin (lecitthin), cephalin (cephalin), ether extracts of red pepper, wheat germ, soybean, pepper, extracts from tomatoes, mainly extracts of the flavonoid pigments.
그런데 합성 항산화제는 생체 내에서 독성을 나타내어 알레르기와 종양을 발생시킬 가능성이 있고, 또한 온도에 약해 한번 열을 가하면 쉽게 파괴되는 등의 단점을 가지고 있다. However, synthetic antioxidants are toxic in vivo and may cause allergies and tumors, and also have weaknesses such as being easily destroyed when heat is applied once due to weak temperature.
또한 천연 항산화제는 합성 항산화제에 비해 생체에 안전하다는 장점이 있으나 그 효과가 약하다는 단점이 있는 것으로 알려져 있다.
In addition, natural antioxidants are known to have the advantages of being safe to the living body compared to synthetic antioxidants, but the effect is weak.
따라서 생체에 독성이 전혀 없으면서도 기존의 천연 항산화제보다 항산화 효과가 뛰어난 천연물 생약을 이용하여 항상화 기능성 조성물을 개발하는 것이 절실하다 하겠다.
Therefore, it is urgent to develop a homeostatic functional composition using natural herbal medicines that are excellent in antioxidant activity than existing natural antioxidants without any toxicity to the living body.
한편 본 발명은 항산화 기능성 조성물로서, 오미자, 인삼, 하수오 및 복분자를 주요 유효성분으로 하고 있는바, 이하 오미자, 인삼, 하수오 및 복분자에 관련하여 살펴본다.On the other hand, the present invention as an antioxidant functional composition, Schizandra, ginseng, sewage and bokbunja as the main active ingredient, bar schisandra, ginseng, sewage and bokbunja look at.
또한 본 발명은 상기 주요 유효성분을 함유하는 제형(劑型)으로서 고제(膏劑)를 제조하기 위해 생지황즙 및 꿀을 이용하고 있는바, 지황에 대해서도 살펴본다.
In addition, the present invention looks at the case of using the raw juice and honey to prepare a solid (膏劑) as a formulation containing the main active ingredient (劑,), look at the sulfur.
먼저, 본 발명은 산화적 스트레스에 기인한 인체의 노화 및 질병 유발 증상이 허로증(虛勞證)(東醫寶鑑 虛勞門, ○ 虛者 皮毛肌肉筋脈骨髓氣血津液 不足是也[綱目], 허(虛)라는 것은 피모(皮毛), 힘살[肌肉], 힘줄[筋脈], 골수(骨髓), 기혈(氣血), 진액(津液) 등이 부족해진 것을 말한다[강목].)에 해당된다고 볼 수 있는바, 기혈음양(氣血陰陽)을 모두 공히 보(補)하는 것이 필요하다는 점에 착안하였음을 밝혀둔다. First, the present invention is the symptoms of aging and disease-induced symptoms of the human body caused by oxidative stress (허) (東 醫 寶 鑑 虛勞 門, ○ 虛 者 皮毛 肌肉 筋脈 骨髓 氣血 津液 不 足 是 也 [綱目, huh (虛), hair, tendon, 힘 tendon, bone marrow (혈), blood donation (진), etc. are lacking [gangmok]. It can be said that it corresponds to), and he noticed that it was necessary to see both the Gi and Yin Yang () 陽) together.
따라서 본 발명은 인삼(氣), 하수오(血), 오미자(陰), 복분자(陽)를 유효성분으로 활용하여 상기 착안점에 따른 조성물을 구성하였다.
Therefore, the present invention utilizes ginseng (하), sewage (血), Schisandra chinensis (복), bokbunja (yang) as an active ingredient to configure a composition according to the above point of interest.
오미자(五味子)는 오미자과에 속한 낙엽 목질등본인 북오미자(北五味子, Schisandra chinensis Baill.) 또는 화중오미자(華中五味子, 南五味子, S. sphenanthera Rehd. et Wils.)의 완숙한 과실을 건조한 것으로, 서리가 내린 후에 채취하여 볕에 말리거나 또는 증기에 쪄서 말린 것이다. Schisandra chinensis Baill. Or Schisandra chinensis Baill., Which is a deciduous wood copy belonging to the Schisandra chinensis , is a dried fruit of Schisandra chinensis , S. sphenanthera Rehd . Et Wils. It is harvested after frost and dried in the sun or steamed.
한의학적으로는, 오미자는 다섯 가지 맛(五味)을 가지고 있으나 신 맛(酸味)이 주(主)이고, 그 성질이 온(溫)하되 조(燥)하지 않아 폐, 심, 신(肺 心 腎) 삼경(三經)에 들어가 위로는 폐기(肺氣)를 수렴(斂)하고, 밑으로는 신음(腎陰)을 자(滋)하며 아울러 삽정지사, 생진(生津), 지한(止汗) 등의 작용을 가지고 있다고 알려져 있다.In Chinese medicine, Schisandra chinensis has five flavors, but the sour taste is the main, and its nature is mild, but it is not crude. ) Entering three scenes, converging wastes in the upper part, moaning underneath, and inserting branch, Saengjin, Jihan It is known to have such action.
특히 최근의 약리학적 연구결과를 보면, 오미자의 주요 약리 성분인 시잔드린(schizandrin(C23H32O6))과 고미신(gomisin) A~Q 등과 같은 성분이 씨에 주로 함유되어 있다고 알려져 있다.
In particular, recent pharmacological studies have shown that the main pharmacological ingredients of Schisandra chinensis (schizandrin (C23H32O6)) and gomisin A ~ Q, etc. are mainly contained in the seeds.
오미자를 항산화 효과에 사용한 종래기술에 대해 살펴보면, 한국공개특허공보 10-2009-0097550호에는 피부의 항산화 효과, 주름방지 효과 등을 위해 오미자로부터 추출한 시잔드린를 주요 활성성분으로 함유하는 화장료 조성물이 기재되어 있다.Looking at the prior art that used Schisandra chinensis for antioxidant effect, Korean Laid-Open Patent Publication No. 10-2009-0097550 describes a cosmetic composition containing sizandrrin extracted from Schisandra chinensis as a main active ingredient for the antioxidant effect and anti-wrinkle effect of the skin. have.
또한 논문 “오미자의 이화학적 특징 및 항산화 활성”(김좌숙 외 1인, 한국식품영양학회지, Vol. 21, No. 1, 35~42, 2008년)에는 증류수로 추출한 오미자 시료가 1,000 ug/ml 농도에서 BHT와 유의적인 차이 없이 유사한 항산화 활성을 나타내었다는 것이 개시되어 있다.
In addition, the paper "Physical Characteristics and Antioxidant Activity of Schizandra chinensis" (Kwak Sook Kim et al., Journal of the Korean Society of Food Science and Nutrition, Vol. It is disclosed that the antioxidant activity was similar to that of BHT without significant difference.
인삼은 두릅나무과(五加科:Araliaceae)에 속한 인삼(人蔘, Panax ginseng C.A. Meyer)의 뿌리를 가공한 것으로, 가을에 줄기와 잎이 마를 때 캐어 말린 것을 백삼이라 하고, 잔뿌리를 제거하고 쪄서 건조한 것을 홍삼이라 하며 설탕에 가공하여 건조한 것을 당삼이라 한다.Ginseng is processed from the root of Panax ginseng CA Meyer, a member of the Araliaceae family. White ginseng is dried when stems and leaves are dried in autumn. Dried red ginseng is processed into sugar and dried is called ginseng.
한의학적으로는, 성질은 약간 따듯하고 맛은 달고 약간 쓰며, 비, 폐, 심장으로 들어가 원기를 보충하고 진액을 만드는 등, 건강 증진과 질병 예방의 효과가 있는 대표적 한약재로 사용되어 왔다.In oriental medicine, it has been used as a representative herbal medicine with the effect of promoting health and preventing disease, such as being slightly warm, sweet and slightly bitter, entering the rain, lungs, and heart to replenish the energy and make a essence.
인삼에는 진세노사이드(ginsenoside)가 약 5.22% 함유되어 있는데, 그 가운데에서 특히 진세노사이드(ginsenoside) Rb1, Rc 및 Rg1의 함유량이 비교적 높다. Ginseng contains about 5.22% of ginsenoside, among which the content of ginsenosides Rb 1 , Rc and Rg 1 is relatively high.
또한 많은 종류의 아미노산(amino acid)과 펩타이드(peptide)류, 비타민(vitamin) A, Bl, B2, C 등이 함유되어 있다.
In addition, it contains many kinds of amino acids (peptides), vitamins (vitamin) A, B 1 , B 2 , C and so on.
인삼을 항산화 효과에 사용한 종래기술에 대해 살펴보면, 한국공개특허공보 10-2009-0112027호에는 최적의 압출성형변수로 인삼을 압출성형하여 항산화 활성을 높이는 것이 기재되어 있다. Looking at the prior art using the ginseng for the antioxidant effect, Korean Patent Publication No. 10-2009-0112027 discloses to increase the antioxidant activity by extruding the ginseng with the optimal extrusion molding parameters.
또한 논문 “인삼의 항산화 작용”(김은혜 외 1인, 고려인삼학회지, Vol. 33, No.1, 1~7, 2009년) 에는 인삼이 활성산소의 손상에 대한 항산화 방어 능력과 함께 산화적 스트레스 발생을 억제하는 작용을 갖고 있다는 것이 개시되어 있다.
In addition, the article “Antioxidant Activity of Ginseng” (Kim Eun-hye et al., Korea Ginseng Society Journal, Vol. 33, No.1, 1 ~ 7, 2009) shows that ginseng oxidative stress along with antioxidant protection against free radical damage It is disclosed that it has an action of suppressing occurrence.
하수오는 마디풀과(蓼科:Polygonaceae)에 속한 다년생 전요초본(纏繞草本)인 하수오 (Polygonum multiflolum Thunb.)의 괴근(塊根)을 건조시킨 것으로 심은지 3~4년 된 것을 봄에는 발아 전에, 가을에는 잎이 마른 뒤 캐서 큰 것은 두 개로 쪼개 햇볕에 말리거나 불에 쬐어 말린다.Sewage is a dried root of Polygonum multiflolum Thunb., A perennial herbaceous plant belonging to the Polygonaceae family, which was planted three to four years before planting in spring and in autumn. After the leaves are dry, cut them into two large pieces and dry them in the sun or on the fire.
여기에서, 하수오는 적하수오(赤何首烏)를 의미하는 것으로서, 우리나라 대한약전외한약규격집에서 적하수오(赤何首烏)를 하수오로, 백하수오(白何首烏)를 백수오로 구분하여 규정하고 있는 것에 따른다.Here, sewage means red sewage (赤 何首烏), which is defined in the Korean Pharmacopoeia Herbal Medicine Standards Collection, which is divided into sewage as sewage and white sewage as white sewage.
참고로, 우리나라와 북한에서는 전통적으로 하수오류(類) 약재를 적하수오 및 백하수오로 구분하여 규정하는 것에 비하여, 중국 및 일본에서는 백하수오에 대해서는 별도로 규정하고 있지 않다. (참고: “하수오와 백하수오의 기원과 명칭에 대한 연구”(최환수 외 3인, 한국한의학연구원논문집 9/1(통권10호), 2003)For reference, in South Korea and North Korea, sewage (類) herbs are traditionally defined as dripping sewage and white sewage, whereas in China and Japan, there is no separate provision for white sewage. (Reference: “Study on the Origins and Names of Sewage and White Sewage” (Cho Hwan-soo et al., Korea Institute of Oriental Medicine 9/1 (Kwon, No. 10), 2003)
한의학적으로는, 그 맛이 쓰고 달고 떫으며 성질은 따뜻하여 간(肝), 심(心),신(腎)경(經)에 귀경한다고 하였으며, 보간(補肝), 익신(益腎), 양혈(養血), 거풍(祛風) 등의 효능으로 보(補)를 주로 하며, 간, 신(肝, 腎)의 이경(二經)에 주로 들어가 신정(腎精)과 간혈(肝血)을 보익(補益)한다.
In Chinese medicine, the taste is bitter, sweet and sweet, and the nature is warm, so it is said that the ear, the heart, the nerve, the ear, and the interpolation, the icy, It is mainly used for the effect of yangtyeol (혈,), gungpung (祛風), etc., and enters the otoscope of the liver, kidney (주로) and Shinjeong (정 精) and liver blood (肝血) ))
하수오를 항산화 효과에 사용한 종래기술에 대하여 살펴보면, 한국공개특허공보 10-2006-0098283호에, 흡연자를 위한 항산화 영양소 보충 조성물에 함유되는 10여종의 물질 중의 하나로 하수오가 개시되어 있다. Looking at the prior art using sewage for the antioxidant effect, Korean Unexamined Patent Publication No. 10-2006-0098283 discloses sewage as one of about 10 substances contained in the antioxidant nutrient supplement composition for smokers.
또한 논문 “식물체 추출물의 항산화성 및 아질산염 소거작용”(한국식품과학회지, Vol. 33, No.5, 626~632, 2001년)에는 하수오 추출물의 DPPH에 대한 전자공여능 측정 결과 50% 이상의 전자공여능이 나타났다는 것이 기재되어 있다.
In addition, the article “Antioxidant and Nitrite Scavenging Activity of Plant Extracts” (Korean Society of Food Science and Technology, Vol. 33, No.5, 626 ~ 632, 2001) shows that electron donating ability of DPPH of sewage extracts was over 50%. It is shown that this appeared.
복분자는 장미과(薔薇科:Rosaceae)에 속한 낙엽관목인 화동복분자(華東覆盆子 Rubus chingii Hu)의 과실(果實)을 건조한 것으로, 초여름에 과실(果實)이 녹색에서 녹황색(綠黃色)으로 변할 때 채취하여 과경(果梗)을 제거하고 끓는 물에 2~4분 정도 익힌 다음 볕에 말린다.Bokbunja is dried fruit of Rubus chingii Hu, a deciduous shrub belonging to the Rosaceae family, and when the fruit turns from green to greenish yellow in early summer. Take out the fruit and remove it and boil it in boiling water for 2 ~ 4 minutes and dry it in the sun.
한의학적으로는, 그 맛이 달고 시며 성질은 따뜻하여 신장과 방관으로 들어가는데, 감미(甘味)는 보익(補益)하고 산미(酸味)는 수렴(收斂)하며 성(性)이 온(溫)하되 조열(燥熱)하지 않아 그 효능이 신양(腎陽)을 보(補)하는 효능이 있어 신허(腎虛)로 인한 하초불고(下焦不固)의 증(證)을 치료하는 양약(良藥)이다.In Oriental medicine, the taste is sweet and sour and the nature is warm, and enters the kidneys and bystanders. The sweetness is complementary, the acidity is converging, the sex is warm, but the heat is low. (燥熱) does not have the effect of Xinyang (腎陽) is effective to treat the symptoms of hypoxia caused by the new license (藥 焦 不 固) is a medicine (良藥).
복분자는 총당(17.3%), 환원당(8.6%), 조단백질(10.6%), 조회분(4.5%), 조지방(3.1%) 및 조섬유(3.9%)와 같은 성분을 함유하고 있으며, 아밀알코올을 포함하는 11종의 알코올류, 발레르산을 포함하는 산(acid)류, 헥산알을 포함하는 20종의 카보닐류, 2-헵타논을 포함하는 5종류의 하이드로카본, 및 메틸팔미트산염을 포함하는 3종류의 에스테르류의 향기성분을 함유하고 있다. Bokbunja contains ingredients such as total sugar (17.3%), reducing sugar (8.6%), crude protein (10.6%), crude ash (4.5%), crude fat (3.1%), and crude fiber (3.9%). 11 kinds of alcohols, acids including valeric acid, 20 kinds of carbonyls including hexanal, 5 kinds of hydrocarbons including 2-heptanone, and methyl palmitate Contains fragrance components of three kinds of esters.
또한 폴리페놀(polyphenol)을 다량 함유하고 있어, 콜레스테롤의 저하, 고혈압이나 동맥경화의 억제, 과산화지질의 생성을 막아 노화의 예방, 혈청중 지질농도의 저하, 중성지질의 생성 억제에 의해 비만 방지 및 모세혈관의 저항력 증진 효과가 있는 것으로 보고되고 있다.
It also contains a large amount of polyphenol, which prevents cholesterol lowering, inhibition of hypertension or atherosclerosis, prevention of lipid peroxidation, prevention of aging, lowering of lipid concentration in serum, inhibition of the generation of neutrophil, It has been reported that there is an effect of increasing the resistance of blood vessels.
복분자를 항산화 효과에 사용한 종래기술에 대하여 살펴보면, 한국공개특허공보 10-2004-0006823호에는 항산화 기능성 건강식품의 성분으로 복분자 알코올추출 엑기스를 사용한 것이 개시되어 있다.Looking at the prior art using the bokbunja for the antioxidant effect, Korean Patent Publication No. 10-2004-0006823 discloses the use of bokbunja alcohol extraction extract as an ingredient of the antioxidant functional health food.
또한 논문 “복분자에 함유된 항산화물질의 동정 및 활성”(윤인 외 6인, 한국식품과학회지, Vol. 34, No.5, 898~904, 2002년)에는 DPPH 실험 결과 복분자 추출물의 EtOAc 가용산성획분에서 강한 활성이 나타났다는 것이 기재되어 있다.
In addition, the article “Identification and Activity of Antioxidants in Bokbunja” (Yoonin et al. 6, Journal of the Korean Food Science and Technology, Vol. 34, No.5, 898 ~ 904, 2002) showed that the solubility of EtOAc in bokbunja extracts was the result of DPPH experiment. It is described that strong activity appeared in the fractions.
지황은 현삼과(玄參科:Scrophulariaceae)에 속한 다년생 초본(草本)인 지황 (Rehmannia glutinosa (Gaertner) Liboschitz)의 뿌리로서 우리나라 각지에서 재배된다.It is the root of Rehmannia glutinosa (Gaertner) Liboschitz, a perennial herb that belongs to Scrophulariaceae.
한의학적으로는, 그 맛이 달고 쓰며 성질은 차가워 심(心), 간(肝), 신(腎)에 귀경(歸經)하는데, 감한질윤(甘寒質潤)한 성미(性味)는 신경(腎經)에 들어가 신음(腎陰)을 자(滋)하여 윤조(潤燥)시키고, 고한(苦寒)한 성미(性味)는 심, 간 혈분(心, 肝 血分)에 들어가 청영량혈하여 숙열(邪熱)을 설열(泄熱)한다. In oriental medicine, the taste is sweet and bitter, and the nature is cold, and the heart, the liver, and the god are deaf. Entering (腎 經) to moan and moisturize, and the cold temper enters the heart and liver blood (heart, 血 分), cheongnyang blood By aging heat (설) to the snow (泄熱).
지황에 함유된 당류로는 D-글루코스(D-glucose), D-갈락토스(D-galactose), D-프룩토스(D-fructose), 수크로스(sucrose), 라피노스(raffinose), 스타치오스(stachyose), 매니노트리오스(manninotriose), 버바스코스(verbascose) 가 있으며 전체 64.9%를 차지한다.
The saccharides contained in dike include D-glucose, D-galactose, D-fructose, sucrose, raffinose and starchose. stachyose, manninotriose and verbascose, accounting for 64.9% of the total.
생지황을 항산화 효과에 사용한 종래기술에 대하여 살펴보면, 논문 “인삼고본환과 그 구성약물군의 항산화 효과”(대한본초학회지, 뢰영성 외 3인, 제18권 제3호, 2003년)에 생지황을 단독으로 실험하지는 않았지만 생지황과 다른 약물들의 혼합군 시료를 실험한 결과 항산화 효과가 나타났다는 것이 기재되어 있다.
Looking at the prior art that used the live sulfur in the antioxidant effect, the article "Antioxidant effect of the ginseng gowanhwan and its constituent drug group" (Korean Journal of Herbology, Rye Young Sung et al., Volume 18, No. 3, 2003) Although not tested, it has been shown that the results of experiments with mixed samples of raw sulfur and other drugs showed antioxidant effects.
정리하여 보면, 종래기술은 오미자, 인삼, 하수오, 복분자를 그 외의 다른 생약들과 혼합하여 사용하고 있음을 알 수 있으며, 또한 오미자, 인삼, 하수오, 복분자 각각의 물질에 대한 항산화 실험결과 각 물질은 일정 정도의 항산화 기능을 보유하고 있음을 알 수 있다.In summary, it can be seen that the prior art uses Schisandra chinensis, Ginseng, Sewao and Bokbunja mixed with other herbal medicines. It can be seen that it has some degree of antioxidant function.
그러나 종래기술에는 오미자, 인삼, 하수오 및 복분자를 주요 유효성분으로서 모두 사용하는 것은 기재되어 있지 않은바, 오미자, 인삼, 하수오 및 복분자를 함께 사용함으로써 나타날 수 있는 항산화 기능에 대해서는 전혀 밝혀내지 못하고 있다.However, the prior art does not describe the use of Schisandra chinensis, Ginseng, Sewao and Bokbun as the main active ingredients, and thus, there is no indication of the antioxidant function that can be obtained by using Schisandra chinensis, Ginseng, Sewao and Bokbunja together.
또한 종래기술에는 오미자, 인삼, 하수오 및 복분자를 주요 유효성분으로 하되, 고제(膏劑)를 제조하기 위해 생지황즙 및 꿀을 이용하고 있는 것은 전혀 기재되어 있지 않다.
In addition, in the prior art, Schisandra chinensis, ginseng, sewage and bokbunja as the main active ingredients, it is not described at all using the raw juice and honey to prepare a solid (膏劑).
따라서 본 발명의 착안점 및 그간의 연구결과로 미루어 볼 때, 오미자, 인삼, 하수오 및 복분자를 복합적으로 섭취하였을 때 항산화 기능의 시너지 효과가 있을 것으로 예상된다.Therefore, from the viewpoint of the present invention and the results of the study, it is expected that synergistic effect of antioxidant function will be expected when ingested Schisandra chinensis, ginseng, sewage and bokbunja in combination.
또한 오미자, 인삼, 하수오 및 복분자에 생지황즙 및 꿀을 포함하여 고제(膏劑)를 형성하게 되면 항산화 효과가 유지됨은 물론 미감이 좋을 것으로 예상된다.In addition, the formation of koji (ginseng) juice and honey in Schisandra chinensis, ginseng, sewage and bokbunja (膏劑) is expected to maintain the antioxidant effect as well as aesthetic sense.
이에 따라 본 발명은 오미자, 인삼, 하수오 및 복분자를 주요 유효성분으로 하되, 생지황즙 및 꿀을 추가로 함유하여 형성한 조성물에 대하여 항산화 활성 및 성분 분석 실험을 수행하였다. Accordingly, the present invention was carried out for the antioxidant activity and component analysis experiments for the composition formed with Schisandra chinensis, ginseng, sewage and bokbunja as the main active ingredients, additionally containing fresh juice and honey.
본 발명의 목적은, 생체에 독성이 전혀 없으면서도 기존의 천연 항산화제보다 항산화 효과가 뛰어난 항상화 기능성 조성물을 제공함에 있다.It is an object of the present invention to provide a homeostatic functional composition having no antioxidant effect and having an excellent antioxidant effect than existing natural antioxidants.
본 발명의 목적은, 오미자, 인삼, 하수오 및 복분자를 유효성분으로 함유하는 항산화 기능성 조성물을 제공함에 있다.An object of the present invention is to provide an antioxidant functional composition containing Schizandra chinensis, Ginseng, Sewage and Bokbunja as active ingredients.
본 발명의 목적은, 오미자, 인삼, 하수오 및 복분자를 유효성분로 함유하되, 생지황 즙 및 꿀을 추가하여 고제(膏劑)로 제형화된 항산화 기능성 조성물 및 식품을 제공함에 있다.It is an object of the present invention to provide an antioxidant functional composition and food containing Schizandra chinensis, Ginseng, Sewage and Bokbunja as active ingredients, and formulated as a solid by adding fresh juice and honey.
본 발명은, 오미자, 인삼, 하수오 및 복분자를 유효성분으로 함유하는 항산화 기능성 조성물을 제공함으로써, 기술적 과제를 해결하고자 한다.
The present invention aims to solve the technical problem by providing an antioxidant functional composition containing Schisandra chinensis, ginseng, sewage and bokbunja as active ingredients.
본 발명은, 오미자, 인삼, 하수오 및 복분자를 포함하는 유효성분에, 약제학적으로 허용되는 담체, 부형제 또는 희석제 등을 추가하여 약제학적 단위 투여형으로 제형화 된 피부노화의 예방 및 치료제를 제공함으로써, 기술적 과제를 해결하고자 한다.The present invention provides a prophylactic and therapeutic agent for skin aging formulated in a pharmaceutical unit dosage form by adding a pharmaceutically acceptable carrier, excipient or diluent to an active ingredient including Schizandra chinensis, Ginseng, Sewage and Bokbunja. To solve technical problems.
여기에서, 담체, 부형제, 희석제로는 토즈, 덱스트로즈, 수크로스, 솔비톨, 만니톨, 자일리톨, 에리스리톨, 말티톨, 전분, 아카시아 고무, 알지네이트, 젤라틴, 칼슘 포스페이트, 칼슘 실리케이트, 셀룰로즈, 메틸 셀룰로즈, 미정질 셀룰로스, 폴리비닐 피롤리돈, 물, 메틸히드록시벤조에이트, 프로필히드록시벤조에이트, 탈크, 마그네슘 스테아레이트 및 광물유를 들 수 있다.Examples of the carrier, excipient and diluent include tosse, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, acacia rubber, alginate, gelatin, calcium phosphate, calcium silicate, cellulose, methyl cellulose, Vaginal cellulose, polyvinylpyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate and mineral oil.
또한 상기 약제학적 투여 형태는 약학적 허용 가능한 염의 형태로도 사용될 수 있고, 또한 단독으로 또는 타 약학적 활성 화합물과 결합뿐만 아니라 적당한 집합으로 사용될 수 있다.
The pharmaceutical dosage forms may also be used in the form of pharmaceutically acceptable salts, and may be used alone or in combination with other pharmaceutically active compounds as well as in a suitable set.
또한 상기 오미자, 인삼, 하수오 및 복분자를 포함하는 유효성분을 제제화 할 경우에는 통상적으로 사용하는 충진제, 증량제, 결합제, 습윤제, 붕해제, 계면 활성제 등의 희석제 또는 부형제를 사용하여 조제될 수 있다.
In addition, when formulating an active ingredient including the Schizandra chinensis, ginseng, sewage and bokbunja can be prepared using a conventional diluent or excipient such as fillers, extenders, binders, wetting agents, disintegrating agents, surfactants.
또한 상기 약제학적 투여 형태는 각각 통상의 방법에 따라 산제, 과립제, 정제, 캡슐제, 현탁액, 에멀젼, 시럽, 에어로졸 등의 경구형 제형, 좌제, 및 멸균 주사용액의 형태로 제형화하여 사용될 수 있다.In addition, each of the pharmaceutical dosage forms may be formulated in the form of powders, granules, tablets, capsules, oral preparations such as suspensions, emulsions, syrups, aerosols, suppositories, and sterilized injection solutions according to conventional methods .
상기 경구 투여를 위한 고형 제제에는 상기 추출물에 적어도 하나 이상의 부형제 예를 들면, 전분은 칼슘 카보네이트(calcium carbonate), 수크로스(sucrose) 또는 락토오스(lactose), 젤라틴 등을 섞어 조제될 수 있다. 또한 단순한 부형제 이외에 마그네슘 스테아레이트, 탈크 같은 윤활제들도 사용될 수 있다.In the solid preparation for oral administration, at least one excipient such as starch may be prepared by mixing calcium carbonate, sucrose, lactose, gelatin or the like in the extract. In addition to simple excipients, lubricants such as magnesium stearate and talc may also be used.
상기 비경구 투여를 위한 제제에는 멸균된 수용액, 비수성용제, 현탁제, 유제, 동결건조 제제, 좌제가 포함될 수 있다. The preparation for parenteral administration may include a sterilized aqueous solution, a non-aqueous solvent, a suspension, an emulsion, a freeze-dried preparation, and a suppository.
상기 비 수성용제, 현탁제로는 프로필렌글리콜(propylene glycol), 폴리에틸렌 글리콜, 올리브 오일과 같은 식물성 기름, 에틸 올레이트와 같은 주사 가능한 에스테르 등이 사용될 수 있다.Examples of the non-aqueous solvent and the suspending agent include propylene glycol, polyethylene glycol, vegetable oil such as olive oil, injectable ester such as ethyl oleate, and the like.
좌제의 기제로는 위텝솔(witepsol), 마크로골, 트윈(tween) 61, 카카오지, 라우린지, 글리세로제라틴 등이 사용될 수 있다.
Examples of the suppository base include witepsol, macrogol, tween 61, cacao butter, laurin, glycerogelatin and the like.
본 발명에 따른 유효성분의 바람직한 투여량은 환자의 상태 및 체중, 질병의 정도, 연령, 성별, 약물형태, 투여경로 및 기간에 따라 다르지만, 당업자에 의해 적절하게 선택될 수 있다.
The preferred dosage of the active ingredient according to the present invention may be appropriately selected by those skilled in the art depending on the condition and the weight of the patient, the degree of disease, age, sex, drug form, administration route and period.
본 발명의 추출물은 쥐, 생쥐, 가축, 인간 등의 포유동물에 다양한 경로로 투여될 수 있다. 투여의 모든 방식은 예상될 수 있는데, 예를 들면, 경구, 직장 또는 정맥, 근육, 피하주사에 의해 투여될 수 있다.
The extract of the present invention can be administered to mammals such as rats, mice, livestock, humans and the like in various routes. All modes of administration may be expected, for example, by oral, rectal or intravenous, muscular, subcutaneous injection.
본 발명은, 오미자, 인삼, 하수오 및 복분자를 유효성분로 함유하되, 생지황 즙 및 꿀을 추가하여 고제(膏劑)로 제형화된 항산화 기능성 조성물 및 식품을 제공함으로써 기술적 과제를 해결하고자 한다.
The present invention is to solve the technical problem by providing an antioxidant functional composition and food formulated as a solid containing Schisandra chinensis, ginseng, sewage and bokbunja as an active ingredient, but added to the saengjihwang juice and honey.
본 발명은, 오미자, 인삼, 하수오 및 복분자를 포함하는 성분 또는 상기 고제(膏劑)로 제형화된 성분에 식품 보조 첨가제를 추가하여 항산화 기능성 식품을 제공함으로써 기술적 과제를 해결하고자 한다.The present invention aims to solve the technical problem by providing an antioxidant functional food by adding a food supplement additive to a component containing Schisandra chinensis, ginseng, sewage and bokbunja or the above formulated ingredients.
상기 성분을 첨가할 수 있는 식품으로는, 예를 들어, 각종 식품류, 음료, 껌, 차, 비타민 복합제, 건강 기능성 식품류 등이 있다.Examples of the food to which the above components can be added include various foods, beverages, gums, teas, vitamin complexes, and health functional foods.
또한 항산화 기능을 목적으로 한 식품 또는 음료에 첨가될 수 있다.It may also be added to foods or beverages for the purpose of antioxidant function.
이때, 식품 또는 음료 중의 상기 성분의 양은 전체 식품 중량의 0.01 내지 20 중량% 이 될 수 있으며, 건강 음료 조성물은 100 ml를 기준으로 0.02 내지 5 g, 바람직하게는 0.3 내지 1 g의 비율로 가할 수 있다.
At this time, the amount of the ingredient in the food or beverage may be 0.01 to 20% by weight of the total food weight, the health beverage composition may be added in a ratio of 0.02 to 5 g, preferably 0.3 to 1 g based on 100 ml have.
본 발명의 건강 기능성 음료 조성물은 상기 성분을 함유하는 외의 다른 성분에는 특별한 제한이 없으며 통상의 음료와 같이 여러 가지 향미제 또는 천연 탄수화물 등을 추가 성분으로서 함유할 수 있다.The health functional beverage composition of the present invention is not particularly limited to the other components containing the above components, and may contain various flavors or natural carbohydrates, etc. as additional components, as in general beverages.
상술한 천연 탄수화물의 예는 모노사카라이드, 예를 들어, 포도당, 과당; 디사카라이드, 예를 들어 말토스, 슈크로스 등 및 폴리사카라이드, 예를 들어 덱스트린, 시클로덱스트린 등과 같은 통상적인 당, 및 자일리톨, 소르비톨, 에리트리톨 등의 당알코올이다. 상술한 것 이외에 향미제로써 천연 향미제(타우마틴, 스테비아 추출물(예를 들어 레바우디오시드 A, 글리시르히진 등) 및 합성 향미제(사카린, 아스파르탐 등)를 유리하게 사용할 수 있다.Examples of the above-mentioned natural carbohydrates are monosaccharides such as glucose, fructose; Disaccharides such as maltose, sucrose and the like and polysaccharides such as dextrins, cyclodextrins and the like, and sugar alcohols such as xylitol, sorbitol and erythritol. In addition to the above, natural flavoring agents (tau martin, stevia extracts (e.g., rebaudioside A, glycyrrhizin, etc.) and synthetic flavors (saccharin, aspartame, etc.) can be advantageously used as flavorings.
상기 천연 탄수화물의 비율은 본 발명의 조성물 100 ml당 일반적으로 약 1 내지 20 g, 바람직하게는 약 5 내지 12 g이다.
The ratio of the natural carbohydrate is generally about 1 to 20 g, preferably about 5 to 12 g per 100 ml of the composition of the present invention.
상기 외에 본 발명의 성분은 여러 가지 영양제, 비타민, 광물(전해질), 합성 풍미제 및 천연 풍미제 등의 풍미제, 착색제 및 중진제(치즈, 초콜릿 등), 펙트산 및 그의 염, 유기산, 보호성 콜로이드 증점제, pH 조절제, 안정화제, 방부제, 글리세린, 알코올, 탄산음료에 사용되는 탄산화제 등을 추가로 함유할 수 있다.In addition to the above, the ingredients of the present invention include various nutrients, vitamins, minerals (electrolytes), flavors such as synthetic flavors and natural flavors, coloring and neutralizing agents (such as cheese and chocolate), pectic acid and salts thereof, organic acids, and protection. It may further contain a sex colloid thickener, a pH adjuster, a stabilizer, a preservative, a glycerin, an alcohol, a carbonation agent used in a carbonated beverage, and the like.
그 밖에 본 발명의 성분은 천연 과일 주스 및 과일 주스 음료 및 야채 음료의 제조를 위한 과육을 함유할 수 있다.In addition, the components of the present invention may contain natural fruit juices and pulp for the production of fruit juice beverages and vegetable beverages.
이러한 성분은 독립적으로 또는 조합하여 사용할 수 있다. 이러한 첨가제의 비율은 그렇게 중요하진 않지만 본 발명의 추출물 100 중량부 당 0 내지 약 20 중량부의 범위에서 선택되는 것이 일반적이다.These components can be used independently or in combination. The proportion of such additives is not so critical, but is generally selected in the range of 0 to about 20 parts by weight per 100 parts by weight of the extract of the present invention.
본 발명인 오미자, 인삼, 하수오 및 복분자를 유효성분으로 함유하는 조성물은, ABST 실험 및 DPPH 실험에서 드러나듯이, 항산화 활성 효과가 현저하다.
Compositions containing Schisandra chinensis, ginseng, sewage and bokbunja as the active ingredients of the present invention, as shown in the ABST experiment and DPPH experiment, has a significant antioxidant activity effect.
본 발명인 오미자, 인삼, 하수오 및 복분자를 함유하되, 생지황 즙 및 꿀로 고제(膏劑)로 형성된 조성물은, ABST 실험 및 DPPH 실험에서 드러나듯이, 항산화 활성 효과가 현저하다.
The composition containing Schisandra chinensis, ginseng, sewage, and bokbunja of the present invention, and formed of solid extract from raw sap juice and honey, has a significant antioxidant activity effect as revealed by ABST experiment and DPPH experiment.
본 발명인 오미자, 인삼, 하수오 및 복분자를 함유하되, 생지황 즙 및 꿀로 고제(膏劑)로 형성된 조성물은, HPLC 실험에서 드러나듯이, 항산화 기능을 위한 주요 약리성분이 유지되고 있는바, 항산화 활성 효과가 현저하다.
The composition containing the present invention Schisandra chinensis, ginseng, sewage, and bokbunja, and the composition formed by the solid juice with raw sulfur juice and honey, as shown in the HPLC experiment, the main pharmacological components for the antioxidant function is maintained, the antioxidant activity effect is remarkable Do.
본 발명인 상기 고제(膏劑)로 형성된 조성물에서, 오미자 및 복분자를 주증(酒蒸)처리하고, 액체 성분(생지황 즙 및 꿀)이 분말 성분(오미자, 인삼, 하수오 및 복분자)의 두 배 이상일 때 미감이 더욱 향상되는 효과가 현저하다.
In the composition formed from the above-mentioned solids of the present invention, the Schizandra chinensis and Bokbunja are treated mainly, and when the liquid components (Jangjihwang juice and honey) are more than twice the powder components (Schisandra chinensis, ginseng, sewage and Bokbunja) This further improving effect is remarkable.
본 발명인 상기 고제(膏劑)로 형성된 조성물에서, 오미자, 인삼, 하수오 및 복분자를 동일 용량으로 하고, 액체 성분이 분말 성분의 두 배이고 또한 생지황 즙 및 꿀이 동일 중량일 경우에 항산화 활성이 보다 강화되는 효과가 현저하다.
In the composition formed from the above-mentioned solid (인) of the present invention, when the Schisandra chinensis, ginseng, sewage and bokbunja in the same dose, the liquid component is twice the powder component and the antioxidant activity is further enhanced when the fresh green juice and honey are the same weight The effect is remarkable.
본 발명인 오미자, 인삼, 하수오 및 복분자를 유효성분으로 함유하는 조성물은, 부작용을 가져오지 않으면서 지속적으로 복용함으로써, 항산화 활성을 개선하는 효과가 현저하다.The composition containing the present invention Schisandra chinensis, ginseng, sewage and bokbunja as an active ingredient, by taking continuously without bringing side effects, the effect of improving the antioxidant activity is remarkable.
도 1a는 본 발명의 실시예에 따른 기능성 조성물에 ABST 항산화 효능실험을 수행한 결과를 표로서 도시한 도면이다.
도 1b는 본 발명의 실시예에 따른 기능성 조성물에 ABST 항산화 효능실험을 수행한 결과를 그래프로서 도시한 도면이다.
도 2a는 본 발명의 실시예에 따른 기능성 조성물에 DPPH 항산화 효능실험을 수행한 결과를 표로서 도시한 도면이다.
도 2b는 본 발명의 실시예에 따른 기능성 조성물에 DPPH 항산화 효능실험을 수행한 결과를 그래프로서 도시한 도면이다.
도 3은 본 발명의 실시예에 따른 기능성 조성물의 성분을 HPLC로 분석한 결과를 그래프로서 도시한 도면이다.Figure 1a is a table showing the results of performing ABST antioxidant efficacy test in a functional composition according to an embodiment of the present invention.
Figure 1b is a graph showing the results of performing the ABST antioxidant efficacy test in the functional composition according to the embodiment of the present invention.
Figure 2a is a table showing the results of performing DPPH antioxidant efficacy test in a functional composition according to an embodiment of the present invention.
Figure 2b is a graph showing the results of the DPPH antioxidant efficacy test performed on the functional composition according to the embodiment of the present invention.
Figure 3 is a graph showing the results of analyzing the components of the functional composition according to an embodiment of the present invention by HPLC.
본 명세서 및 청구범위에 사용된 용어나 단어는 통상적이거나 사전적인 의미로 한정해서 해석되어서는 안 되며, 발명자는 그 자신의 발명을 가장 최선의 방법으로 설명하기 위해 용어의 개념을 적절하게 정의할 수 있다는 원칙에 입각하여 본 발명의 기술적 사상에 부합하는 의미와 개념으로 해석되어야만 한다.
The terms and words used in the present specification and claims should not be construed as limited to ordinary or dictionary terms and the inventor may properly define the concept of the term in order to best describe its invention It should be construed as meaning and concept consistent with the technical idea of the present invention.
따라서 본 명세서에 기재된 실시예와 도면에 도시된 구성은 본 발명의 가장 바람직한 일 실시예에 불과할 뿐이고 본 발명의 기술적 사상을 모두 대변하는 것은 아니므로, 본 출원시점에 있어서 이들을 대체할 수 있는 다양한 균등물과 변형예들이 있을 수 있음을 이해하여야 한다.
Therefore, the embodiments described in the present specification and the configurations shown in the drawings are merely the most preferred embodiments of the present invention and are not intended to represent all of the technical ideas of the present invention. Therefore, various equivalents It should be understood that water and variations may be present.
이하 첨부된 도면을 참조하여 본 발명의 바람직한 실시예를 상세히 설명하기로 한다.
Hereinafter, preferred embodiments of the present invention will be described in detail with reference to the accompanying drawings.
실시예 1. Example 1.
오미자, 인삼, 하수오 및 복분자를 포함한 고제(膏劑)의Koji, including Schisandra chinensis, Ginseng, Sewao and Bokbunja
제조 Produce
1-1. 재료가공1-1. Material processing
1차로 약재에 붙어 있는 흙 등의 이물질을 수작업으로 깨끗이 제거한 후에, 2 차로 오미자, 인삼, 하수오 및 복분자는 분쇄기를 이용하여 분말을 형성하고, 생지황은 압착기를 이용하여 즙을 추출하며, 꿀은 끓여서(약 1시간) 수분을 제거한다.First, after removing the foreign substances such as soil, which is attached to the medicine, by hand, secondly, Schisandra chinensis, Ginseng, Sewao and Bokbunja are formed by using a grinder to form a powder. (About 1 hour) Remove moisture.
여기에서, 오미자의 경우 주요 약리성분이 씨에 주로 함유되어 있는바 오미자 전체를 이용하여 분말을 형성한다.Here, in the case of Schisandra chinensis constituents are mainly contained in the seed bar to form a powder using the whole Schisandra chinensis.
또한 오미자 및 복분자의 경우, 미리 주증(酒蒸) 단계를 거친 것을 이용하여 분말을 형성할 수도 있다.In addition, in the case of Schizandra chinensis and Bokbunja, it is also possible to form a powder by using a preliminary step (酒蒸) step in advance.
3차 가공 단계는 고제(膏劑)를 형성할 때 덩어리가 지어지지 않게 하기 위한 과정으로서, 오미자, 인삼, 하수오 및 복분자 분말을 다시 미세한 체로 걸러주며, 생지황 즙은 삼베로 걸러준다.
The third processing step is to prevent clumping when forming solids, and the Schisandra chinensis, ginseng, sewage, and bokbunja powder are again filtered through a fine sieve, and the raw turmeric juice is filtered through burlap.
1-2. 재료혼합1-2. Material mixing
오미자, 인삼, 하수오 및 복분자 분말과 생지황 즙 및 꿀을 혼합하되, 반죽 덩어리가 뭉치지 않고 고르게 되도록 혼합한다.Mix Schisandra chinensis, Ginseng, Sewao and Bokbunja powder with raw distilled juice and honey, but mix so that dough dough is not aggregated and even.
여기에서, 오미자, 인삼, 하수오 및 복분자의 배합비율은 동일 용량으로 처리하며, 오미자 특유의 신맛을 일정 정도 보정하기 위해 생지황 즙 및 꿀의 양을 조정할 수 있다. Here, the mixing ratio of Schisandra chinensis, ginseng, sewage and bokbunja is treated at the same dose, and the amount of raw sap juice and honey can be adjusted to correct a certain sour taste unique to Schisandra chinensis.
혼합용기는 항아리를 사용하였으며, 나무주걱을 이용하여 혼합하였다.
A mixing vessel was used as a jar and mixed with a wooden spatula.
1-3. 중탕1-3. Water bath
중탕용기(쇠로 된 것)에 항아리 밑받침(항아리 밑 부분이 중탕용기에서 떠 있게 하기 위한 나무토막 종류)를 준비하고, 항아리 입구를 항아리 뚜껑(5장의 기름 먹인 한지)으로 밀봉한 후 광목 끈으로 입구를 잡아맨다.Prepare the base of the jar in the bath container (made of iron) (wood chips to keep the bottom of the jar floating in the bath container), seal the jar opening with the jar lid (5 sheets of oiled Korean paper) Grabs it.
3일간 계속 중탕하되 물이 증발되어 표면의 위치가 항아리 속의 혼합 반죽된 재료의 높이 아래로 내려가지 않도록 뜨거운 물로 지속적으로 보충한다.Continue to soak for 3 days, but continue to replenish with hot water so that the water does not evaporate and the position of the surface does not fall below the height of the mixed dough in the jar.
4일째에, 불을 끄고 항아리를 들어 올려 꺼내 놓고 중탕 용기의 뜨거운 물을 버리고 다시 항아리를 중탕용기에 넣고 찬물을 부어서 1일간 담가둔다.On
다시 2일째에 1일간 2차 중탕하여 완성한다.
On the second day, complete the second bath for a day.
참고예 1. 실험 준비Reference Example 1. Experiment Preparation
1-1. 시료 준비1-1. Sample Preparation
실시예 1의 제조방법과 동일하게 고제(膏劑)를 형성하되, 오미자, 인삼, 하수오 및 복분자의 배합비율은 동일 용량으로 처리하며, 분말(오미자, 인삼, 하수오 및 복분자)과 혼합되는 점성 액체 성분(생지황 즙 및 꿀)의 양을 조정하여 시료 1~5를 형성하였다.A viscous liquid component is formed in the same manner as in Preparation Example 1, but the mixing ratio of Schisandra chinensis, Ginseng, Sewage and Bokbun is treated at the same dose, and mixed with powder (Schisandra chinensis, Ginseng, Sewage and Bokbunja).
시료 1은 주증(酒蒸) 처리한 오미자 및 복분자를 분말로 형성하여 제작된 시료이다.
시료(No.1~5) 무게의 20.0 배량 (w/v)에 해당하는 증류수 (3차)를 가하여 고루 희석한 뒤, 시린지 필터 (나일론, 0.45 μm)로 여과한 액을 원료환산농도 50 mg/mL로 정하고 이를 최종농도 5000, 2500, 1250, 625, 312.5 μg/mL가 되도록 희석하여 실험하였다.
Diluted water (third) corresponding to 20.0 times (w / v) of the weight of the samples (No. 1 to 5) was added and diluted, and the filtered solution with a syringe filter (nylon, 0.45 μm) was converted to a raw material conversion concentration of 50 mg. / mL was determined and diluted to a final concentration of 5000, 2500, 1250, 625, 312.5 μg / mL experiment.
참고예 2. 미감 및 소화실험 Reference Example 2. Aesthetic and Digestion Experiment
1-1. 실험준비1-1. Preparation for experiment
시료 1~5에 대하여, 우석대 한의대에 재학중인 학생 10명을 관능검사 요원으로 선별하여 미감 및 소화 실험을 수행하였다. For
관능평가는 7점 측정법 (1점: 가장 나쁘다, 2점: 나쁘다. 3점: 조금 나쁘다. 4점: 보통이다. 5점: 조금 좋다. 6점: 좋다. 7점: 가장 좋다)으로 맛, 향, 조직감에 대해 수행하였다.
Sensory evaluation is a 7-point measurement method (1 point: worst, 2 points: bad. 3 points: a little bad. 4 points: normal. 5 points: a little good. 6 points: good. 7 points: best.) The smell, texture was performed.
1-2. 실험결과1-2. Experiment result
호number
도Degree
편차Standard
Deviation
편차Standard
Deviation
편차Standard
Deviation
편차Standard
Deviation
편차Standard
Deviation
편차Standard
Deviation
편차Standard
Deviation
편차Standard
Deviation
편차Standard
Deviation
편차Standard
Deviation
직Direct
감feeling
편차Standard
Deviation
편차Standard
Deviation
편차Standard
Deviation
편차Standard
Deviation
편차Standard
Deviation
전체적인 기호도 부분을 고려했을 때, 시료1이 맛에서는 52점, 향에서는 55점, 조직감에서는 54점을 획득하여 선호도에서 가장 높은 것으로 나타났다.Considering the overall preference,
이는, 오미자 및 복분자는 씨를 포함하고 있어서 분말로 만들었다고 해도 소화장애를 호소하는 경우가 있던 점을 참고하여, 오미자 및 복분자를 주증(酒蒸)함으로써 소화장애를 개선한 결과로 파악된다.
This is considered to be the result of improving digestive disorders by referring to the fact that Schizandra chinensis and Bokbunja contain seeds, which sometimes complains of digestive disorders even if they are made of powder.
시료 2의 경우, 분말의 비가 다른 시료에 비해 많기 때문에 맛 및 조직감 등 전체적인 부분이 낮게 나왔다고 보인다.
In the case of
시료 3은 생지황 즙의 양이 너무 많아서 묽게 형성되었고 또한 생지황 특유의 향과 신맛이 좀 더 강해지는 경향이 있었다.
시료 4는 오미자 및 복분자를 주증 처리하지 않은 점을 제외하고 시료 1과 배합비율이 동일하였으며, 시료 1 다음으로 기호도가 높았다.
시료 5는 액체 성분이 제일 많았던 시료로서, 시료 1, 시료 4 다음의 순위로 기호도가 조사되었다.
총괄적으로 보면, 미감 및 소화 실험에서는 시료 1의 배합이 가장 우수한 것으로 조사되었으며, 또한 액체 성분의 총 중량은 분말 총 중량의 두 배가 가장 적합하다는 것을 알 수 있다.
Collectively, in the taste and digestion experiments, the formulation of
실험예 1. Experimental Example 1
ABST 항산화 효능 실험ABST Antioxidant Effect Experiment
1-1. ABST 시약1-1. ABST reagent
발색변화를 이용한 항산화 효능시험을 변형하여 시험하였다. 5 mM 인산칼륨 완충액 (pH 7.4)에 ABTS (2,2'-azinobis-(3-ethylbenzothiazoline-6- sulfonic acid))를 7 mM 농도로 녹이고, 여기에 2.45 mM 과황산칼륨 (K2S2O8)을 0.5 배량 가하고 실온에서 12 시간 이상 방치하여 암청색이 되도록 하였다.Antioxidant efficacy test using color change was modified. Dissolve ABTS (2,2'-azinobis- (3-ethylbenzothiazoline-6-sulfonic acid)) in 5 mM potassium phosphate buffer (pH 7.4) at 7 mM concentration and add 0.5x 2.45 mM potassium persulfate (K2S2O8) It was added and allowed to stand at room temperature for 12 hours or more to give a dark blue color.
매 시험 직전에 인산칼륨 완충액을 가하여 96혈 조직배양 플레이트 (Microtest 3072, BD Falcon, USA)에 200 μL씩 주입하고 흡광도 측정기 (Spectra Max 340, Molecular Devices, USA)를 이용하여 734 nm 흡광도를 측정하였을 때 1.0±0.02가 되도록 희석한 것을 ABTS 시액으로 사용하였다.
Immediately before each test, 200 μL of potassium phosphate buffer was added to 96 blood tissue culture plates (Microtest 3072, BD Falcon, USA) and absorbance was measured using an absorbance meter (Spectra Max 340, Molecular Devices, USA). When diluted to 1.0 ± 0.02 was used as the ABTS solution.
1-2. 양성대조군1-2. Positive control group
양성대조군은 TroloxTM를 에탄올에 최종농도 62.5 μM로 희석하여 사용하였고 보정액은 인산칼륨 완충액을 사용하였다.
The positive control group was diluted with TroloxTM in ethanol to a final concentration of 62.5 μM and the correction solution was potassium phosphate buffer.
1-3. 실험방법1-3. Experimental Method
96혈 조직배양 플레이트 (Microtest 3072, BD Falcon, USA)의 각 혈에 농도별로 준비한 추출물, 기준액 및 대조액 20 μL를 각각 가한 뒤, ABTS 시액 180 μL를 각 혈에 가하고 실온에서 5 분간 방치한 뒤 흡광도 측정기 (Spectra Max 340, Molecular Devices, USA)로 734 nm 흡광도를 측정하였다.After adding 20 μL of extract, reference solution and control solution, each concentration of 96 blood tissue culture plate (Microtest 3072, BD Falcon, USA) to each blood, 180 μL of ABTS solution was added to each blood and left at room temperature for 5 minutes. 734 nm absorbance was measured with an absorbance meter (Spectra Max 340, Molecular Devices, USA).
시험은 3 회 반복하였으며, 보정액의 흡광도치를 영점으로 하였다. ABTS 라디칼 소거능은 백분율로 환산하였다.환산식은 다음과 같다.
The test was repeated three times, and the absorbance value of the correction liquid was zero. ABTS radical scavenging ability was converted into percentage. The conversion formula is as follows.
라디칼 소거능(%) = 100 - (시험군의 흡광도치/ 대조군의 흡광도치) X 100
Radical scavenging activity (%) = 100-(absorbance value of test group / absorbance value of control group)
1-4. 통계처리1-4. Statistical processing
실험군의 유의성 검증은 일원분산분석 (one-way ANOVA) 및 독립표본 t-test를 실시하여 대조군에 대해 P < 0.05 인 경우 유의한 것으로 판정하였다. .
The significance of the experimental group was determined by one-way ANOVA and independent sample t- test, which was significant when P <0.05 for the control group. .
1-5. 실험결과1-5. Experiment result
도 1a는 본 발명의 실시예에 따른 기능성 조성물에 ABST 항산화 효능실험을 수행한 결과를 표로서 도시하고, 도 1b는 그래프로서 도시한 도면이다.
Figure 1a is a table showing the results of performing the ABST antioxidant efficacy test to the functional composition according to an embodiment of the present invention, Figure 1b is a diagram showing a graph.
도 1a, 1b를 참조하여 보면, ABTS 라디칼 소거능의 경우, 모든 시료에서 농도의존적인 효능을 보였으며, NO. 4-5-2-3-1 순으로 강한 활성이 나타났다.Referring to Figure 1a, 1b, in the case of ABTS radical scavenging ability, all samples showed concentration-dependent efficacy, NO. Strong activity was shown in the order of 4-5-2-3-1.
특히 농도 1250 μg/mL에서는 시료 4가 87.34%로서, 시료 1의 47.40% 에 비해 두 배에 가까운 효능 차이가 보였다. In particular, at concentrations of 1250 μg / mL,
여기에서, 양성대조군의 활성은 라디칼 소거능 99.87%이었다.
Here, the activity of the positive control group was 99.87% of the radical scavenging activity.
주목할 점은, 시료 1 내지 시료 5까지 유의미한 정도로 항산화 효능을 나타내었다는 점이며, 특히 시료 4의 배합 비율로서 중탕 처리 과정을 통해 고제(膏劑)를 형성하면 항산화 활성이 강화되었다는 점을 알 수 있다.It is noted that, from
즉 액체 성분(생지황 즙 및 꿀)이 분말 성분(오미자, 인삼, 하수오 및 복분자)의 두 배이고 또한 생지황 즙 및 꿀이 동일 중량일 경우에 보다 항산화 활성이 강화되었다고 볼 수 있겠다.
In other words, the liquid component (Saengjihwang juice and honey) is twice the powder components (Schisandra chinensis, ginseng, sewage and bokbunja) and the antioxidant activity was enhanced when the saengjihwang juice and honey are the same weight.
실험예 2. Experimental Example 2
DPPH 항산화 효능 실험DPPH Antioxidant Efficacy Experiment
1-1. DPPH 시약1-1. DPPH Reagent
발색변화를 이용한 항산화 효능시험을 변형하여 시험하였다. 에탄올에 DPPH (2,2-diphenyl-1-picrylhydrazyl)를 200 μM 농도로 녹인 것을 DPPH 시액으로 사용하였다.
Antioxidant efficacy test using color change was modified. DPPH (2,2-diphenyl-1-picrylhydrazyl) dissolved in ethanol at a concentration of 200 μM was used as a DPPH reagent.
1-2. 양성대조군1-2. Positive control group
양성대조군은 TroloxTM를 에탄올에 최종농도 62.5 μM로 희석하여 사용하였고 보정액은 에탄올을 사용하였다.
The positive control group was diluted with TroloxTM in ethanol to a final concentration of 62.5 μM and ethanol was used as the calibration solution.
1-3. 실험방법1-3. Experimental Method
96혈 조직배양 플레이트 (Microtest 3072, BD Falcon, USA)의 각 혈에 농도별로 준비한 추출물, 기준액 및 대조액 20 μL를 각각 가한 뒤, DPPH 시액 180 μL를 각 혈에 가하고 실온에서 30 분간 방치한 뒤 흡광도 측정기 (Spectra Max 340, Molecular Devices, USA)로 515 nm 흡광도를 측정하였다. After adding 20 μL of each extract, reference solution and control solution to each blood of 96 blood tissue culture plate (Microtest 3072, BD Falcon, USA), 180 μL of DPPH solution was added to each blood and left at room temperature for 30 minutes. 515 nm absorbance was measured with an absorbance meter (Spectra Max 340, Molecular Devices, USA).
시험은 3 회 반복하였으며, 보정액의 흡광도치를 영점으로 하였다. DPPH 라디칼 소거능은 백분율로 환산하였다. 환산식은 다음과 같다.
The test was repeated three times, and the absorbance value of the correction liquid was zero. DPPH radical scavenging ability was converted in percentage. The conversion formula is as follows.
라디칼 소거능(%) = 100 - 시험군의 흡광도치/대조군의 흡광도치) X 100
Radical scavenging activity (%) = 100-absorbance value of the test group / absorbance value of the control group)
1-4. 통계처리1-4. Statistical processing
실험군의 유의성 검증은 일원분산분석 (one-way ANOVA) 및 독립표본 t-test를 실시하여 대조군에 대해 P < 0.05 인 경우 유의한 것으로 판정하였다. .
The significance of the experimental group was determined by one-way ANOVA and independent sample t- test, which was significant when P <0.05 for the control group. .
1-5. 실험결과1-5. Experiment result
도 2a는 본 발명의 실시예에 따른 기능성 조성물에 DPPH 항산화 효능실험을 수행한 결과를 표로서 도시하고, 도 2b는 그래프로서 도시한 도면이다.
Figure 2a is a table showing the results of performing DPPH antioxidant efficacy test on the functional composition according to an embodiment of the present invention, Figure 2b is a graph showing a graph.
도 2a, 2b를 참조해보면, 최종농도 2500 μg/mL까지는 농도의존적인 효능을 보이나, 시료 5를 제외하고는 2500 μg/mL 이상의 농도에서 오히려 활성이 감소하는 것으로 나타났다.Referring to Figures 2a, 2b, the final concentration up to 2500 μg / mL showed a concentration-dependent efficacy, but except for
이는 시료의 색상이 황색으로써 고농도에서 515 nm의 흡광도에 영향을 미친 것으로 판단된다.This is judged to affect the absorbance of 515 nm at high concentration as the color of the sample is yellow.
ABTS 시험 결과에 비추어 볼 때, 고농도에서도 항산화능의 증가 경향은 유지된다고 판단함이 타당할 것으로 보인다.
In light of the results of the ABTS test, it is reasonable to conclude that even at high concentrations, the trend of increasing antioxidant activity is maintained.
효능의 차이는 No. 4-5-2-3-1 순으로 ABTS 시험에서와 동일하였으며 특히 농도 2500 μg/mL에서는 시료 4가 77.68%로서 시료 1의 35.15%에 비해 두 배 이상의 효능 차이가 보였다.The difference in efficacy is no. In the order of 4-5-2-3-1, the same as in the ABTS test, especially at concentration 2500 μg / mL,
여기에서, 양성대조군의 활성은 라디칼 소거능 96.51%였다.
Herein, the activity of the positive control group was 96.51% of the radical scavenging activity.
주목할 점은, ABST 실험예와 마찬가지로, 시료 1 내지 시료 5까지 유의미한 정도로 항산화 효능을 나타내었다는 점이며, 특히 시료 4의 배합 비율로서 중탕 처리 과정을 통해 고제(膏劑)를 형성하면 항산화 활성이 강화되었다는 점을 알 수 있다.
It is noteworthy that, as in the ABST experimental example, the antioxidant activity of the
실험예 3. HPLC를 이용한 성분 분석 실험Experimental Example 3. Component Analysis Using HPLC
1-1. 실험준비1-1. Preparation for experiment
HPLC (High Performance Liquid Chromatography)를 이용하여 시료 4 로부터 표준물질 시잔드린(schisandrin) 및 진세노사이드(ginsenoside) Rb1, Rb2, Rc, Re, Rf 및 Rg1의 함유 여부 측정(chemical fingerprinting)을 위해 정성분석을 실시하였다. ((재)전주생물소재연구소에서 확립된 방법으로 HPLC를 이용함)Qualitative Analysis for Chemical Fingerprinting of Standards Schisandrin and Ginsenosides Rb1, Rb2, Rc, Re, Rf and Rg1 from
실험조건은, HPLC(Agilent 1200 series with MWD (Multi-Wavelength Detector)), 디텍터(Detector: UV 203 nm), 컬럼(Column :Agilent Zorbax XDB C18 (4.6 × 150 mm, 5 μm pore size)), 컬럼온도(Column temp.) 는 35 °C, 모바일 페이스(Mobile phase)는 H2O / Acetonitrile (A/B) as a gradient elution Initiation 3%B, 10 min 18% B, 25 min 22%B, 55 min 30%B, 75 min 40%B, 80 min 50%B, 85 min 18% B, 90 min 3%B, 플로우레이트(Flowa rate)는 0.8 mL/min, 인젝션(Injection)은 20 μL이다.
Experimental conditions were HPLC (Agilent 1200 series with MWD (Multi-Wavelength Detector), detector (Detector: UV 203 nm), column (Column: Agilent Zorbax XDB C18 (4.6 × 150 mm, 5 μm pore size)), column Column temp. Is 35 ° C, mobile phase is H2O / Acetonitrile (A / B) as a
1-2. 표준물질 정보1-2. Reference material information
해당 실험으로 사용된 농도의 표기는 모두 프리베이스(free base)로서 기재하였다.
The notation of concentrations used in the experiments were all described as free base.
1-2-1. Ginsenoside Rb11-2-1. Ginsenoside Rb1
(3beta,12beta)-20-[(6-O-beta-D-Glucopyranosyl-beta-D-glucopyranosyl)oxy]-
12-hydroxydammar-24-en-3-yl2-O-beta-D-glucopyranosyl-beta-D-glucopyranosideCommon Name: Ginsenoside Rb1
(3beta, 12beta) -20-[(6-O-beta-D-Glucopyranosyl-beta-D-glucopyranosyl) oxy]-
12-hydroxydammar-24-en-3-yl2-O-beta-D-glucopyranosyl-beta-D-glucopyranoside
1-2-2. Ginsenoside Rg11-2-2. Ginsenoside Rg1
(3β,6α,12β)-3,12-Dihydroxydammar-24-ene-6,20-diyl bis-β-D-glucopyranosideCommon Name: Ginsenoside Rg1
(3β, 6α, 12β) -3,12-Dihydroxydammar-24-ene-6,20-diyl bis-β-D-glucopyranoside
1-2-3. Ginsenoside Re1-2-3. Ginsenoside re
1-2-4. Ginsenoside Rf1-2-4. Ginsenoside Rf
(3β,6α,12β)-3,12,20-Trihydroxydammar-24-en-6-yl 2-O-β-D-glucopyranosyl-β-D-glucopyranosideCommon Name: Ginsenoside Rf
(3β, 6α, 12β) -3,12,20-Trihydroxydammar-24-en-6-yl 2-O-β-D-glucopyranosyl-β-D-glucopyranoside
1-2-5. Ginsenoside Rb21-2-5. Ginsenoside Rb2
20-((6-O-alpha-L-Arabinopyranosyl-beta-D-glucopyranosyl)oxy)-12beta-
hydroxydammar-24-en-3beta-yl2-O-beta-D-glucopyranosyl- beta-D-glucopyranosideCommon Name: Ginsenoside Rb2
20-((6-O-alpha-L-Arabinopyranosyl-beta-D-glucopyranosyl) oxy) -12beta-
hydroxydammar-24-en-3beta-yl2-O-beta-D-glucopyranosyl- beta-D-glucopyranoside
1-2-6. Ginsenoside Rc1-2-6. Ginsenoside Rc
20-[(6-O-alpha-L-Arabinofuranosyl-beta-D-glucopyranosyl)oxy]-12b-
hydroxydammar-24-en-3b-yl2-O-beta-D-glucopyranosyl- beta-D-glucopyranosideCommon Name: Ginsenoside Rc
20-[(6-O-alpha-L-Arabinofuranosyl-beta-D-glucopyranosyl) oxy] -12b-
hydroxydammar-24-en-3b-yl2-O-beta-D-glucopyranosyl- beta-D-glucopyranoside
1-2-7. Schisandrin1-2-7. Schisandrin
Schisandrin (7CI)Common Name: Schisandrin
Schisandrin (7CI)
1-3. 시료조제1-3. Sample preparation
시료 4 중량1.2753 g을 취하여 80% methanol aq. (v/v) 10 mL을 첨가한 후 현탁 추출한 후 시료들은 × 9,700 g 하에서 5 min 동안 원심분리 후 2-fold 희석하여 20 μL씩 HPLC에 주입하였다.
Take 4 weight 1.2753 g of
1-4. 시약1-4. reagent
1-5. 실험결과1-5. Experiment result
도 3은 본 발명의 실시예에 따른 기능성 조성물의 성분을 HPLC로 분석한 결과를 그래프로서 도시한 도면이다.
Figure 3 is a graph showing the results of analyzing the components of the functional composition according to an embodiment of the present invention by HPLC.
블랭크(Blank) 시료에 대하여 각 진세노사이드 표준 용액(ginsenoside standard solution) 중 진세노사이드(ginsenoside) Rg1의 피크 리텐션 타임(peak retention time)은 약 23 분, 진세노사이드(ginsenoside) Rf는 약 50 분, 진세노사이드(ginsenoside) Rb1은 약 60 분, 시잔드린(schisandrin)은 약 77 분으로 나타났다.
For blank samples, the peak retention time of ginsenoside Rg1 in each ginsenoside standard solution is about 23 minutes, and the ginsenoside Rf is about 50 minutes, ginsenoside Rb1 was about 60 minutes, and chisandrin was about 77 minutes.
하지만, 시료 중의 진세노사이드(ginsenoside) Re, Rc 및 Rb2의 경우는 피크 인텐시티(peak intensity)가 약하여 확인하지 못하였다.
However, in the case of ginsenosides Re, Rc and Rb2 in the sample, the peak intensity was weak and could not be confirmed.
주목할 점은, 오미자 및 인삼을 포함하여 중탕 처리한 고제(膏劑)에서 항산화 활성 성분으로서의, 오미자의 주요 약리성분인 시잔드린 (schisandrin) 및 인삼에 포함되어 있는 진세노사이드(ginsenoside) Rb1, Rg1 및 Rf가 분석되었다는 점이다.
It is noteworthy that ginsenosides Rb 1 and Rg included in ginseng and schisandrin, which are the main pharmacological components of Schisandra chinensis, as antioxidant active ingredients in water-treated solids containing Schizandra chinensis and Ginseng. 1 and Rf were analyzed.
참고예2, 실험예 1, 실험예 2 및 실험예 3을 총괄적으로 보면, 오미자, 인삼, 하수오 및 복분자를 주요 유효성분으로 포함하는 조성물은 유의미한 정도로 항산화 활성을 가지고 있는 것을 알 수 있다.Looking at Reference Example 2, Experimental Example 1, Experimental Example 2 and Experimental Example 3, it can be seen that the composition containing Schisandra chinensis, Ginseng, Sewage and Bokbunja as the main active ingredients has a significant degree of antioxidant activity.
또한 오미자 및 복분자를 주증(酒蒸)처리하고, 액체 성분(생지황 즙 및 꿀)이 분말 성분(오미자, 인삼, 하수오 및 복분자)의 두 배 이상일 때 미감이 향상될 수 있다는 점을 알 수 있다.It can also be seen that the aesthetics can be improved when the Schizandra chinensis and Bokbunja are main treated, and the liquid ingredients (Saengjihwang juice and honey) are more than twice the powder components (Schisandra chinensis, Ginseng, Sewao and Bokbunja).
또한 오미자, 인삼, 하수오 및 복분자를 동일 용량으로 하고, 액체 성분이 분말 성분의 두 배이고 또한 생지황 즙 및 꿀이 동일 중량일 경우에 항산화 활성이 보다 강화되었다고 할 수 있겠다. In addition, it is said that antioxidant activity is enhanced when Schisandra chinensis, ginseng, sewage and bokbunja have the same dose, the liquid component is twice the powder component, and the saengjihwang juice and honey are the same weight.
또한 중탕 처리 과정을 통해 형성된 고제(膏劑)에서도, 항산화 기능을 할 수 있는 오미자 및 인삼의 주요 약리성분이 분석되었다는 점을 알 수 있다.In addition, it can be seen that the main pharmacological components of Schisandra chinensis and ginseng, which can function as antioxidants, were also analyzed in solid products formed through the bath treatment.
Claims (9)
생지황(生地黃, Rehmannia glutinosa (Gaertner) Liboschitz) 즙 및 꿀을 추가하여 고제(膏劑)로 제형화하되, 상기 생지황 즙 및 꿀의 중량은 동일 중량이고, 상기 생지황 즙 및 꿀의 총 중량이 상기 오미자, 인삼, 하수오 및 복분자 총 중량의 두 배 이상인 것을 특징으로 하는 항산화 기능성 조성물.
Omija ( Schisandra chinensis Baill.), Ginseng (人蔘, Panax ginseng CA Meyer), Shou (何首烏, Polygonum multiflorum Thunberg) and Bokbunja (覆盆子Rubus chingii Hu) are each formed into powder and contain the same weight.
It is formulated as solid by adding juice and honey of Rehmannia glutinosa (Gaertner) Liboschitz), wherein the weight of the juice and honey is the same weight, and the total weight of the juice and honey is Schisandra chinensis Antioxidant functional composition, characterized in that more than twice the total weight of ginseng, sewage and bokbunja.
An antioxidant functional food characterized by further adding a food acceptable food additive to the composition according to claim 4.
상기 오미자 및 복분자는 주증(酒蒸) 처리된 것을 이용하는 것을 특징으로 하는 항산화 기능성 식품.
The method of claim 7,
The Schizandra chinensis and Bokbunja Antioxidant functional foods, characterized in that using the main treatment (酒蒸).
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020110037075A KR101295125B1 (en) | 2011-04-21 | 2011-04-21 | A pharmaceutical with anti-oxidative activity, and a healthful food with the pharmaceutical |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020110037075A KR101295125B1 (en) | 2011-04-21 | 2011-04-21 | A pharmaceutical with anti-oxidative activity, and a healthful food with the pharmaceutical |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20120119265A KR20120119265A (en) | 2012-10-31 |
KR101295125B1 true KR101295125B1 (en) | 2013-08-09 |
Family
ID=47286552
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020110037075A KR101295125B1 (en) | 2011-04-21 | 2011-04-21 | A pharmaceutical with anti-oxidative activity, and a healthful food with the pharmaceutical |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR101295125B1 (en) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20160011175A (en) | 2015-09-18 | 2016-01-29 | 재단법인 전남생물산업진흥원 | Food composition comprising cynanchum wilfordii potentiating testosterone excretion as an active ingredient |
KR20160011174A (en) | 2015-09-18 | 2016-01-29 | 재단법인 전남생물산업진흥원 | Food composition comprising cynanchum wilfordii potentiating testosterone excretion as an active ingredient |
KR20210143499A (en) | 2020-05-20 | 2021-11-29 | 참들애바이오푸드영농조합법인 | Manufacturing method of health food having antioxidant activity containing fermented polygonum multiflorum complex extracts and the health food having antioxidant activity thereby |
KR20220031147A (en) | 2020-09-03 | 2022-03-11 | 주식회사 라파데오 | Functional composition for pet and use of thereof |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104223054A (en) * | 2013-06-24 | 2014-12-24 | 山东明仁福瑞达制药股份有限公司 | Anti-fatigue health food composition |
CN103876148A (en) * | 2014-04-02 | 2014-06-25 | 陈迎霞 | Spleen-strengthening and Qi-tonifying anticancer ointment and preparation method thereof |
CN104171797A (en) * | 2014-07-28 | 2014-12-03 | 无限极(中国)有限公司 | Application of ginseng and polygonum multiflorum compound polysaccharide in preparation of health foods with anti-aging effect |
KR102226265B1 (en) * | 2018-12-14 | 2021-03-11 | 대한민국 | Method for Preparating functional grain syrup comprising Cynanchi wilfordii extract and functional grain syrup preparated thereby |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20050114168A (en) * | 2004-05-31 | 2005-12-05 | 박명환 | New manufacturing process for Kyung-Ok-Go and new formulation thereof. |
-
2011
- 2011-04-21 KR KR1020110037075A patent/KR101295125B1/en active IP Right Grant
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20050114168A (en) * | 2004-05-31 | 2005-12-05 | 박명환 | New manufacturing process for Kyung-Ok-Go and new formulation thereof. |
Non-Patent Citations (3)
Title |
---|
곽병준 외 4명, 대한예방한의학회지 (2003) 제7권 제2호 pp.85-96 * |
장은희 외 2명, 한국조리과학회지 (1996) 제12권 제3호 pp.372-376 * |
한기선 외 3명, 대한한방내과학회지 (1998) 제19권 제2호 pp.411-430 * |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20160011175A (en) | 2015-09-18 | 2016-01-29 | 재단법인 전남생물산업진흥원 | Food composition comprising cynanchum wilfordii potentiating testosterone excretion as an active ingredient |
KR20160011174A (en) | 2015-09-18 | 2016-01-29 | 재단법인 전남생물산업진흥원 | Food composition comprising cynanchum wilfordii potentiating testosterone excretion as an active ingredient |
KR20210143499A (en) | 2020-05-20 | 2021-11-29 | 참들애바이오푸드영농조합법인 | Manufacturing method of health food having antioxidant activity containing fermented polygonum multiflorum complex extracts and the health food having antioxidant activity thereby |
KR20220031147A (en) | 2020-09-03 | 2022-03-11 | 주식회사 라파데오 | Functional composition for pet and use of thereof |
Also Published As
Publication number | Publication date |
---|---|
KR20120119265A (en) | 2012-10-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR101295125B1 (en) | A pharmaceutical with anti-oxidative activity, and a healthful food with the pharmaceutical | |
KR101360231B1 (en) | Pharmaceutical composition for preventing or treating liver cancer comprising herbal extracts | |
KR102136052B1 (en) | Composition for Liver Protection Containing Hub Extract and Beverage Thereof | |
KR20120038611A (en) | Pharmaceutical composition for preventing or treating liver cancer comprising herbal extracts | |
KR20180010961A (en) | Composition for preventing, treating or improving muscle atrophy comprising complex extracts | |
KR101915031B1 (en) | Method for producing functional dutch coffee for relieving woman menopausal symptoms using Punica granatum fruit and Pueraria lobata root extracts | |
US20220226409A1 (en) | Composition for stimulating of myogenesis and prevention of muscle damage containing ginseng extract | |
KR20120038612A (en) | Pharmaceutical composition for preventing or treating renal cell carcinoma comprising herbal extracts | |
KR101360232B1 (en) | Pharmaceutical composition for preventing or treating renal cell carcinoma comprising herbal extracts | |
KR100874778B1 (en) | Composition for the prevention and treatment of menopausal diseases comprising fermented Cheonggukjang extract | |
KR20190053107A (en) | A composition comprising the complex extract for antiobesity of women | |
KR20100133079A (en) | Herbal extracts composition for the prevention of alcoholic fatty liver, hyperlipidemia and hangover | |
Lal et al. | Traditional, medicinal and nutraceutical values of minor fruit: Longan | |
El-Hadidy et al. | Omar. Protective Effect on Lipids Profile of Lion’s Foot (Alchemilla Vulgaris) Leaves against Ccl4 Toxicity and its Fortified to Guava and Mango Pulp | |
KR101456127B1 (en) | A composition for increasing bone growth | |
KR102178199B1 (en) | a composition comprising an extract of Rhus verniciflua and Eucommia ulmoides, as an active ingredient for preventing or treating obesity | |
KR20140137185A (en) | Composition comprising an extract of combined crude drug including Angelicae Dahurica for preventing and treating inflammatory disease or allergic disease | |
KR101344189B1 (en) | A Composition comprising an extract of fermented or non-fermented Lonicerae Flos and Citri Reticulatae Pericarpium for treating or preventing obesity | |
KR101360233B1 (en) | Pharmaceutical composition for preventing or treating lung cancer comprising herbal extracts | |
KR100832520B1 (en) | A composition for the treatment or prevention of osteoporosis comprising an extract of capsosiphon fulvecense | |
KR101791574B1 (en) | Pharmaceutical composition for preventing or treating female menopausal disorder comprising an extract of black rice aleurone layer | |
KR20150002048A (en) | A composition for preventing wrinkle of skin and anti aging of skin | |
KR102355104B1 (en) | Pharmaceutical and functional food composition comprising complex extract of Brassica rapa for prevention or treatment of respiratory disease | |
KR102651713B1 (en) | Chocolate composition for relieving hangovers comprising Hovenia Dulcis fruit and Velvet Antlers, and the manufacturing method of chocolate for relieving hangovers using the same | |
KR101814132B1 (en) | Composition for Treatment of Lung Cancer and Functional Food Comprising Extract of Patriniae Radix |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant | ||
FPAY | Annual fee payment |
Payment date: 20160620 Year of fee payment: 4 |
|
FPAY | Annual fee payment |
Payment date: 20170913 Year of fee payment: 5 |
|
FPAY | Annual fee payment |
Payment date: 20180725 Year of fee payment: 6 |
|
FPAY | Annual fee payment |
Payment date: 20190717 Year of fee payment: 7 |